[go: up one dir, main page]

WO2023011338A1 - 抗CD79b×CD3双特异性抗体及其用途 - Google Patents

抗CD79b×CD3双特异性抗体及其用途 Download PDF

Info

Publication number
WO2023011338A1
WO2023011338A1 PCT/CN2022/108881 CN2022108881W WO2023011338A1 WO 2023011338 A1 WO2023011338 A1 WO 2023011338A1 CN 2022108881 W CN2022108881 W CN 2022108881W WO 2023011338 A1 WO2023011338 A1 WO 2023011338A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
heavy chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/108881
Other languages
English (en)
French (fr)
Inventor
伍伟伟
王杰
何开杰
李莉
周帅祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Priority to AU2022324406A priority Critical patent/AU2022324406A1/en
Priority to CN202280053838.XA priority patent/CN117897404A/zh
Priority to EP22852051.6A priority patent/EP4382538A4/en
Priority to JP2024520682A priority patent/JP2024536358A/ja
Priority to CA3231174A priority patent/CA3231174A1/en
Priority to US18/294,212 priority patent/US20240343799A1/en
Publication of WO2023011338A1 publication Critical patent/WO2023011338A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Definitions

  • the present invention relates generally to the fields of immunology and antibody engineering. Specifically, the present invention relates to CD79b monospecific antibodies and novel bispecific antibodies specifically binding to CD79b and CD3. Furthermore, the present invention relates to nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said nucleic acids or vectors, pharmaceutical compositions comprising said antibodies or antigen-binding fragments thereof. In addition, the present invention relates to the application of these antibodies, pharmaceutical compositions, etc. in the immunotherapy, prevention and/or diagnosis of diseases.
  • CD79b belongs to the immunoglobulin superfamily and forms a heterodimer with CD79a, which together with surface globulin form the BCR receptor complex. BCR itself does not have a domain for transmitting signals. Once an antigen binds to BCR, the CD79a/b heterodimer is responsible for transmitting signals downstream, which is crucial to maintaining the function of the entire B cell. Studies have shown that after knocking out CD79b, B cells will be restricted to the pre-B stage and cannot further mature.
  • NEL non-Hodgkin's lymphoma
  • the first-line treatment for B-cell NHL has a high recurrence rate (DLBCL first-line treatment recurrence rate is 30-40%), and the prognosis of relapsed patients is poor (DLBCL average 9- December OS), with limited late-stage therapy.
  • DLBCL first-line treatment recurrence rate is 30-40%, and the prognosis of relapsed patients is poor (DLBCL average 9- December OS), with limited late-stage therapy.
  • the number of newly diagnosed and relapsed and refractory patients is huge every year (there are about 80,000 new patients each year in China and the United States), especially in China, where the annual death toll reaches about 50,000, which is more than twice that of the United States.
  • Antibody-drug conjugates against CD79b have shown certain curative effect on NHL patients clinically, but some patients still develop drug resistance, and patients still have a large unmet need for improved therapy for NHL.
  • the present invention provides a bispecific antibody that binds to CD79b and CD3 with high target specificity and high affinity, especially by binding to CD79b expressed on the surface of tumor cells so that T cells can be recruited to the bispecific around tumor cells Antibodies fulfill this need.
  • One aspect of the present invention relates to a novel CD79b-binding antibody or antigen-binding fragment thereof.
  • the invention provides an antibody or antigen-binding fragment thereof that binds to CD79b, comprising a heavy chain variable region VH and/or a light chain variable region VL, wherein,
  • the VH comprises three complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3 contained in the VH shown in SEQ ID NO:4, and the VL comprises the VL shown in SEQ ID NO:9 LCDR1, LCDR2 and LCDR3;
  • CDRs complementarity determining regions
  • the VH comprises three complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3 contained in the VH shown in SEQ ID NO:14, and the VL comprises the VL contained in SEQ ID NO:19 LCDR1, LCDR2 and LCDR3;
  • CDRs complementarity determining regions
  • the invention provides an antibody or antigen-binding fragment thereof that binds to CD79b, comprising a heavy chain variable region VH and/or a light chain variable region VL, wherein,
  • the VH comprises complementary determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:11; HCDR2 comprises SEQ ID NO:2 or SEQ ID NO : the amino acid sequence shown in 12; HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 13;
  • VL comprises complementarity determining regions (CDR) LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO:6 or SEQ ID NO:16; LCDR2 comprises SEQ ID NO:7 or SEQ ID The amino acid sequence shown in NO:17; LCDR3 comprises the amino acid sequence shown in SEQ ID NO:8 or SEQ ID NO:18.
  • CDR complementarity determining regions
  • the invention provides an antibody or antigen-binding fragment thereof that binds to XXX, comprising a heavy chain variable region VH and/or a light chain variable region VL, wherein
  • the VH comprises complementary determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1; HCDR2 comprises the amino acid sequence shown in SEQ ID NO:2; HCDR3 comprises the amino acid sequence shown in SEQ ID NO The amino acid sequence shown in: 3;
  • the VL comprises complementarity determining region (CDR) LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 6; LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 7 ; LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 8;
  • the VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:11; HCDR2 comprises the amino acid sequence shown in SEQ ID NO:12; HCDR3 comprises the amino acid sequence shown in SEQ ID NO:12; The amino acid sequence shown in: 13;
  • the VL comprises complementarity determining region (CDR) LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 16; LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 17 ; LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 18;
  • the invention provides an antibody or antigen-binding fragment thereof that binds to CD79b, comprising a heavy chain variable region VH and/or a light chain variable region VL, wherein,
  • (ii) comprises or consists of the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:14; or
  • amino acid changes comprising one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) compared with the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 14 ) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions), preferably, the amino acid changes do not occur in the CDR region;
  • (ii) comprises or consists of the amino acid sequence shown in SEQ ID NO:9 or SEQ ID NO:19; or
  • amino acid changes comprising one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) compared with the amino acid sequence shown in SEQ ID NO: 9 or SEQ ID NO: 19 ) amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions), preferably, the amino acid changes do not occur in the CDR region.
  • the invention provides an antibody or antigen-binding fragment thereof that binds CD79b comprising
  • the invention provides an antibody or antigen-binding fragment thereof that binds CD79b comprising
  • the invention provides an antibody or antigen-binding fragment thereof that binds CD79b comprising a heavy chain and/or a light chain, wherein
  • (ii) comprises or consists of the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:15; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions), preferably, the amino acid changes do not occur in the CDR region of the heavy chain, more preferably, the amino acid changes do not occur in the CDR region of the heavy chain In the heavy chain variable region;
  • (ii) comprises or consists of the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 20; or
  • amino acid sequence of amino acid changes (preferably amino acid substitutions, more preferably amino acid conservative substitutions), preferably, the amino acid changes do not occur in the CDR region of the light chain, more preferably, the amino acid changes do not occur in the CDR region of the light chain in the light chain variable region.
  • the invention provides an antibody or antigen-binding fragment thereof that binds CD79b comprising
  • the heavy chain of amino acid sequence and comprises and the aminoacid sequence shown in SEQ ID NO:10 has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% % or 99% identity to the light chain of the amino acid sequence;
  • the heavy chain of amino acid sequence and comprises and the aminoacid sequence shown in SEQ ID NO:20 has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% % or 99% identity to the light chain of the amino acid sequence;
  • the invention provides an antibody or antigen-binding fragment thereof that binds CD79b comprising
  • the invention provides an isolated nucleic acid encoding a CD79b-binding antibody or antigen-binding fragment thereof of the invention, a vector comprising the nucleic acid, a host cell comprising the nucleic acid or the vector.
  • the present invention provides a method for preparing the CD79b-binding antibody or antigen-binding fragment thereof of the present invention, the method comprising culturing the host of the present invention under conditions suitable for expressing the nucleic acid encoding the present invention cell.
  • the invention provides immunoconjugates and pharmaceutical compositions comprising a CD79b-binding antibody or antigen-binding fragment thereof of the invention.
  • the present invention also provides the use of the CD79b-binding antibody or its antigen-binding fragment, immunoconjugate or pharmaceutical composition of the present invention in the preparation of drugs for preventing and/or treating tumors.
  • the present invention also provides a method for preventing and/or treating tumors, the method comprising administering to a subject an effective amount of the CD79b-binding antibody or antigen-binding fragment thereof, immunoconjugate or drug of the present invention combination.
  • the present invention also relates to a method for detecting CD79b in a sample, the method comprising (a) contacting an antibody or an antigen-binding fragment thereof of the present invention; and (b) detecting the formation of a complex between the antibody or an antigen-binding fragment thereof and CD79b .
  • Another aspect of the present invention also discloses a novel bispecific antibody targeting both CD79b and CD3, a polynucleotide encoding the bispecific antibody, a vector comprising the polynucleotide, a polynucleotide comprising the polynucleotide A host cell of acid or carrier, and the use of the bispecific antibody in treating, preventing and/or diagnosing diseases related to CD79b activity in individuals.
  • the present invention provides a bispecific antibody (anti-CD79b ⁇ CD3 bispecific antibody) that specifically binds to CD79b and binds to CD3, comprising (i) an anti-CD79b antibody or a fragment thereof, and (ii) an anti- CD3 antibody or fragment thereof.
  • the present invention provides an anti-CD79b ⁇ CD3 bispecific antibody in 1+1 format, which consists of four symmetrical polypeptide chains, wherein the left half consists of the first light chain and the first heavy chain, The right half consists of the second heavy chain and the second light chain, the first light chain and the first heavy chain are antibody heavy chain and light chain targeting CD79b or CD3 respectively, the second heavy chain and the second light chain are respectively Consists of antibody heavy and light chains targeting CD3 or CD79b.
  • the present invention provides an anti-CD79b ⁇ CD3 bispecific antibody in a 1+1 format, wherein the first light chain and the first heavy chain specifically bind to CD79b, and the second heavy chain and the second light chain specifically bind Binds CD3.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein the first light chain comprises ID NO: 9, 3 light chain CDRs included in 19 or 29, the first heavy chain includes 3 heavy chain CDRs included in SEQ ID NO: 4, 14 or 24, the second heavy chain includes selected from SEQ ID NO: 4, 3 heavy chain CDRs included in 14 or 24, the second heavy chain includes The 3 heavy chain CDRs included in ID NO: 34 or 44, the second light chain includes the 3 light chain CDRs included in SEQ ID NO: 39 or 49.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises the first light chain, the first heavy chain, the second heavy chain and the second light chain, the first light chain and the first heavy chain Bind CD79b, second heavy chain and second light chain bind CD3, where:
  • the first light chain comprises 3 light chain CDRs from SEQ ID NO:9
  • the first heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:4
  • the second heavy chain comprises from SEQ ID The 3 heavy chain CDRs contained in NO:34
  • the second light chain comprises 3 light chain CDRs contained in SEQ ID NO:39;
  • the first light chain comprises 3 light chain CDRs from SEQ ID NO:9
  • the first heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:4
  • the second heavy chain comprises from SEQ ID The 3 heavy chain CDRs contained in NO:44
  • the second light chain comprises 3 light chain CDRs contained in SEQ ID NO:49;
  • the first light chain comprises 3 light chain CDRs from SEQ ID NO:19
  • the first heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:14
  • the second heavy chain comprises from SEQ ID
  • the second light chain comprises 3 light chain CDRs contained in SEQ ID NO:39;
  • the first light chain comprises 3 light chain CDRs contained in SEQ ID NO:19
  • the first heavy chain comprises 3 heavy chain CDRs contained in SEQ ID NO:14
  • the second heavy chain comprises 3 heavy chain CDRs contained in SEQ ID NO:14
  • the 3 heavy chain CDRs contained in NO:44, and the second light chain comprises 3 light chain CDRs contained in SEQ ID NO:49;
  • the first light chain comprises 3 light chain CDRs from SEQ ID NO:29
  • the first heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:24
  • the second heavy chain comprises from SEQ ID
  • the second light chain comprises 3 light chain CDRs contained in SEQ ID NO:39; or
  • the first light chain comprises 3 light chain CDRs contained in SEQ ID NO:29
  • the first heavy chain comprises 3 heavy chain CDRs contained in SEQ ID NO:24
  • the second heavy chain comprises 3 heavy chain CDRs contained in SEQ ID NO:24.
  • the second light chain contains 3 light chain CDRs contained in SEQ ID NO:49.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein the first light chain comprises ID NO: 9, 19 or 29 comprises 3 light chain CDRs and has at least 90% identity with SEQ ID NO: 9, 19 or 29 VL, the first heavy chain comprises selected from SEQ ID NO: 4, 14 or 24 comprising 3 heavy chain CDRs and a VH having at least 90% identity to SEQ ID NO: 4, 14 or 24, the second heavy chain comprising 3 heavy chains comprised in SEQ ID NO: 34 or 44 chain CDRs and a VH having at least 90% identity with SEQ ID NO: 34 or 44, the second light chain comprises 3 light chain CDRs selected from SEQ ID NO: 39 or 49 and is identical to SEQ ID NO: 39 or 49 VLs with at least 90% identity.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein:
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:9 and at least 90% identical to SEQ ID NO:9
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:4 A VH with at least 90% identity to the 3 light chain CDRs of SEQ ID NO:4 and a second heavy chain comprising the 3 heavy chain CDRs from SEQ ID NO:34 and at least 90% identity to SEQ ID NO:34 A VH of 90% identity
  • the second light chain comprising a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:39 and having at least 90% identity to SEQ ID NO:39;
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:9 and at least 90% identical to SEQ ID NO:9
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:4 A VH with at least 90% identity to the 3 light chain CDRs of SEQ ID NO:4 and a second heavy chain comprising the 3 heavy chain CDRs from SEQ ID NO:44 and at least 90% identity to SEQ ID NO:44 A VH of 90% identity
  • the second light chain comprising a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:49 and having at least 90% identity to SEQ ID NO:49;
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:19 and at least 90% identical to SEQ ID NO:19
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:14 A VH with at least 90% identity to the 3 light chain CDRs of SEQ ID NO: 14 and a second heavy chain comprising 3 heavy chain CDRs from SEQ ID NO: 34 and at least 90% identity to SEQ ID NO: 34 A VH of 90% identity
  • the second light chain comprising a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:39 and having at least 90% identity to SEQ ID NO:39;
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:19 and at least 90% identical to SEQ ID NO:19
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:14 3 light chain CDRs and a VH having at least 90% identity with SEQ ID NO: 14, the second heavy chain comprising 3 heavy chain CDRs from SEQ ID NO: 44 and having at least 90% identity with SEQ ID NO: 44 A VH of 90% identity, the second light chain comprising a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:49 and having at least 90% identity to SEQ ID NO:49;
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:29 and at least 90% identical to SEQ ID NO:29
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:24 A VH having at least 90% identity to the 3 light chain CDRs of SEQ ID NO:24
  • the second heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:34 and has at least 90% identity to SEQ ID NO:34 A VH of 90% identity
  • the second light chain comprising a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:39 and having at least 90% identity to SEQ ID NO:39; or
  • the first light chain comprises a VL derived from the 3 light chain CDRs contained in SEQ ID NO:29 and at least 90% identical to SEQ ID NO:29
  • the first heavy chain comprises a VL derived from those contained in SEQ ID NO:24 A VH having at least 90% identity to the 3 light chain CDRs of SEQ ID NO:24
  • the second heavy chain comprises 3 heavy chain CDRs from SEQ ID NO:44 and has at least 90% identity to SEQ ID NO:44 A VH of 90% identity
  • the second light chain comprises a VL derived from the 3 light chain CDRs comprised by SEQ ID NO:49 and is at least 90% identical to SEQ ID NO:49.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein:
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:6 or consists of said amino acid sequence, and LCDR2 comprises the amino acid sequence of SEQ ID NO:7 or consists of said amino acid sequence, LCDR3 comprises the amino acid sequence of SEQ ID NO:8 or consists of said amino acid sequence, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:1 or consists of said amino acid sequence, HCDR2 comprises The amino acid sequence of SEQ ID NO:2 or consists of said amino acid sequence, HCDR3 comprises or consists of said amino acid sequence of SEQ ID NO:3; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID The amino acid sequence of NO:31 or consists of said amino acid sequence, HCDR2 comprises the amino acid sequence of SEQ ID NO:32 or consists of said amino acid sequence, HCDR
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:6 or consists of said amino acid sequence, and LCDR2 comprises the amino acid sequence of SEQ ID NO:7 or consists of said amino acid sequence, LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:8, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO:1, and HCDR2 comprises The amino acid sequence of SEQ ID NO:2 or consists of said amino acid sequence, HCDR3 comprises or consists of said amino acid sequence of SEQ ID NO:3; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID
  • HCDR2 comprises the amino acid sequence of SEQ ID NO:42 or consists of said amino acid sequence
  • HCDR3 comprises the amino acid sequence
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 16 or consists of said amino acid sequence, and LCDR2 comprises the amino acid sequence of SEQ ID NO: 17 or consists of said amino acid sequence, LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO:11, and HCDR2 comprises The amino acid sequence of SEQ ID NO:12 or consists of said amino acid sequence, HCDR3 comprises or consists of said amino acid sequence of SEQ ID NO:13; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID
  • HCDR2 comprises the amino acid sequence of SEQ ID NO:32 or consists of said amino acid sequence
  • HCDR3 comprises the amino
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 16 or consists of said amino acid sequence, and LCDR2 comprises the amino acid sequence of SEQ ID NO: 17 or consists of said amino acid sequence, LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO:11, and HCDR2 comprises The amino acid sequence of SEQ ID NO:12 or consists of said amino acid sequence, HCDR3 comprises or consists of said amino acid sequence of SEQ ID NO:13; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID
  • HCDR2 comprises the amino acid sequence of SEQ ID NO:42 or consists of said amino acid sequence
  • HCDR3 comprises the amino
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:26 or consists of said amino acid sequence, LCDR2 comprises the amino acid sequence of SEQ ID NO:27 or consists of said amino acid sequence, LCDR3 comprises the amino acid sequence of SEQ ID NO:28 or consists of said amino acid sequence, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:21 or consists of said amino acid sequence, HCDR2 comprises The amino acid sequence of SEQ ID NO:22 or consists of said amino acid sequence, HCDR3 comprises the amino acid sequence of SEQ ID NO:23 or consists of said amino acid sequence; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID The amino acid sequence of NO:31 or consists of said amino acid sequence, HCDR2 comprises the amino acid sequence of SEQ ID NO:32 or consists of said amino acid sequence
  • the first light chain comprises LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:26 or consists of said amino acid sequence, LCDR2 comprises the amino acid sequence of SEQ ID NO:27 or consists of said amino acid sequence, LCDR3 comprises the amino acid sequence of SEQ ID NO:28 or consists of said amino acid sequence, the first heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:21 or consists of said amino acid sequence, HCDR2 comprises The amino acid sequence of SEQ ID NO:22 or consists of said amino acid sequence, HCDR3 comprises the amino acid sequence of SEQ ID NO:23 or consists of said amino acid sequence; the second heavy chain comprises HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises SEQ ID The amino acid sequence of NO:41 or consists of said amino acid sequence, HCDR2 comprises the amino acid sequence of SEQ ID NO:42 or consists of said amino acid sequence
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein the first light chain comprises NO:9, the VL shown in 19 or 29, the first heavy chain comprises selected from the VH shown in SEQ ID NO:4, 14 or 24, the second heavy chain comprises selected from the VH shown in SEQ ID NO:34 or 44 VH, the second light chain comprises a VL selected from SEQ ID NO: 39 or 49.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein:
  • the first light chain comprises VL shown in SEQ ID NO:9
  • the first heavy chain comprises VH shown in SEQ ID NO:4
  • the second heavy chain comprises VH shown in SEQ ID NO:34
  • the second light chain comprises SEQ ID NO: VL shown in ID NO:39;
  • the first light chain comprises VL shown in SEQ ID NO:9
  • the first heavy chain comprises VH shown in SEQ ID NO:4
  • the second heavy chain comprises VH shown in SEQ ID NO:44
  • the second light chain comprises SEQ VL shown in ID NO:49;
  • the first light chain comprises VL shown in SEQ ID NO:19
  • the first heavy chain comprises VH shown in SEQ ID NO:14
  • the second heavy chain comprises VH shown in SEQ ID NO:34
  • the second light chain comprises SEQ ID NO: VL shown in ID NO:39;
  • the first light chain comprises VL shown in SEQ ID NO:19
  • the first heavy chain comprises VH shown in SEQ ID NO:14
  • the second heavy chain comprises VH shown in SEQ ID NO:44
  • the second light chain comprises SEQ ID NO: VL shown in ID NO:49;
  • the first light chain comprises VL shown in SEQ ID NO:29
  • the first heavy chain comprises VH shown in SEQ ID NO:24
  • the second heavy chain comprises VH shown in SEQ ID NO:34
  • the second light chain comprises SEQ ID NO:29 VL shown in ID NO:39; or
  • the first light chain comprises VL shown in SEQ ID NO:29
  • the first heavy chain comprises VH shown in SEQ ID NO:24
  • the second heavy chain comprises VH shown in SEQ ID NO:44
  • the second light chain comprises SEQ VL shown in ID NO:49.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention comprises a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein the first heavy chain and the second heavy chain Contain the same or different Fc regions.
  • the Fc regions included in the first heavy chain and the second heavy chain have "knob” and “hole” structures respectively, and the knob-hole structures interact to stabilize the spatial structure of the bispecific antibody.
  • variable regions contained in the first heavy chain and the second heavy chain are homologous or heterologous to the Fc region.
  • the variable regions comprised in the first heavy chain and the second heavy chain are linked directly to the Fc region or via a linker.
  • the linker is a flexible linker commonly used in the art.
  • the invention provides an anti-CD79b ⁇ CD3 bispecific antibody comprising a first light chain, a first heavy chain, a second heavy chain and a second light chain, wherein:
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 10 or consisting of SEQ ID NO:10;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:5 %, 99% or more sequence identity, or consists of SEQ ID NO: 5;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 35;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 40 , a sequence of 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 40;
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 10 or consisting of SEQ ID NO:10;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:5 %, 99% or more sequence identity, or consists of SEQ ID NO: 5;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 45;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 50 , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 50;
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20 or consisting of SEQ ID NO:20;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:15 %, 99% or more sequence identity, or consists of SEQ ID NO: 15;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 35;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 40 , a sequence of 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 40;
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20 or consisting of SEQ ID NO:20;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:15 %, 99% or more sequence identity, or consists of SEQ ID NO: 15;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 45;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 50 , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 50;
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30 or consisting of SEQ ID NO:30;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:25 %, 99% or more sequence identity, or consists of SEQ ID NO: 25;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 35;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 40 , a sequence of 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 40;
  • the first light chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30 or consisting of SEQ ID NO:30;
  • the first heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of SEQ ID NO:25 %, 99% or more sequence identity, or consists of SEQ ID NO: 25;
  • the second heavy chain comprises at least 90%, 91%, 92%, 93%, 94%, A sequence of 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO: 45;
  • the second light chain comprises at least 90%, 91% with SEQ ID NO: 50 , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity, or consists of SEQ ID NO:50.
  • the light chain variable domain of the first light chain and the heavy chain variable domain of the first heavy chain pair to form the antigen recognition site for CD79b
  • the heavy chain variable domain of the second heavy chain domain and the light chain variable domain of the second light chain pair to form the antigen recognition site of CD3.
  • the respective Fc domains of the first and second heavy chains interact to form an Fc region.
  • the respective Fc domains of the first heavy chain and the second heavy chain contain mutations that stabilize interactions, eg, contain "knob into socket" mutations.
  • the present invention also provides a polynucleotide (nucleic acid) encoding the anti-CD79b ⁇ CD3 bispecific antibody of the present invention, a vector comprising the polynucleotide, preferably an expression vector.
  • the invention provides a host cell comprising a polynucleotide or vector of the invention.
  • the present invention also provides a method for producing the anti-CD79b ⁇ CD3 bispecific antibody of the present invention, comprising step (i) cultivating the host of the present invention under conditions suitable for expressing the anti-CD79b ⁇ CD3 bispecific antibody of the present invention cells, and (ii) recovering the anti-CD79b ⁇ CD3 bispecific antibody of the invention.
  • the present invention provides a diagnostic kit and a pharmaceutical composition comprising the anti-CD79b ⁇ CD3 bispecific antibody of the present invention. Further, the use of the anti-CD79b ⁇ CD3 bispecific antibody, diagnostic kit or pharmaceutical composition of the present invention is also provided for treating, preventing and/or diagnosing diseases related to CD79b activity, especially for treating, Prevention and/or diagnosis of non-Hodgkin's lymphoma.
  • the present invention provides a method for treating a disease associated with CD79b activity, comprising administering a therapeutically effective amount of the anti-CD79b ⁇ CD3 bispecific antibody of the present invention, or the pharmaceutical composition of the present invention to a patient in need .
  • the disease is a cancer overexpressing CD79b, more preferably the disease is non-Hodgkin's lymphoma.
  • Figure 10 Activation of human CD8+ T cells detected by flow cytometry of exemplary antibodies.
  • Figure 11 Flow cytometry detection of the release of cytokine IFN- ⁇ accompanied by the killing process of human CD8+ T cells on tumor cells induced by an example antibody.
  • Figure 12 Flow cytometry detection of the release of cytokine TNF ⁇ accompanied by the killing of tumor cells by human CD8+ T cells induced by an example antibody.
  • Figure 14 Exemplary antibodies promote CD8+ T cell proliferation.
  • Figure 15 Exemplary antibodies promote human CD4+ T cell proliferation.
  • Figure 17 Tumor inhibitory effect of exemplary antibodies in the Ramos tumor-bearing humanized mouse model.
  • Figure 18 PK of bispecific antibodies in mice.
  • antibody is used herein in the broadest sense and encompasses a variety of antibody constructs including, but not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, humanized antibodies, chimeric antibodies, multispecific antibodies (e.g. , bispecific antibody), single-chain antibody, whole antibody, or antibody fragment thereof that exhibits the desired antigen-binding activity.
  • a whole antibody will usually comprise at least two full-length heavy chains and two full-length light chains, but in some cases may comprise fewer chains, for example antibodies naturally occurring in camelids may comprise only heavy chains.
  • antigen-binding fragment refers to a molecule, other than an intact antibody, that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds.
  • antigen-binding fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab') 2 ; diabodies (dAbs); linear antibodies; single chain antibodies (e.g. scFv); Antibodies (single domain antibodies); antigen-binding fragments of bivalent or bispecific antibodies; camelid antibodies; and other fragments that exhibit the desired ability to bind antigen (eg, CD79b and/or CD3).
  • bind and “specifically bind” mean that the binding of the antibody is selective for the antigen and can be distinguished from unwanted or non-specific interactions.
  • the ability of an antibody to bind a particular antigen can be determined by enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), or optical interferometry of biofilm layers (ForteBio) or other conventional binding assays known in the art.
  • ELISA enzyme-linked immunosorbent assay
  • SPR surface plasmon resonance
  • FormeBio optical interferometry of biofilm layers
  • the antibody has a KD of about 1 ⁇ 10 -7 or less, a KD of about 1 ⁇ 10 -8 or less, a KD of about 1 ⁇ 10 -9 or less, about 1 ⁇ 10 -10 or A lower KD, about 1 ⁇ 10 ⁇ 11 or lower KD binds to CD79b or CD3, then the antibody is an antibody that “specifically binds to CD79b or CD3”.
  • antibodies that specifically bind CD79b or CD3 may be cross-reactive with CD79b or CD3 proteins from other species.
  • antibodies specific for human CD79b or CD3 may, in some embodiments, cross-react with cynomolgus CD79b or CD3. Methods of determining cross-reactivity include those described in the Examples as well as standard assays known in the art, for example by using bioluminescent interferometry, or flow cytometry techniques.
  • single-chain variable fragment or "scFv” is a small molecule genetically engineered antibody, which uses genetic engineering methods at the DNA level to combine the heavy chain variable region (VH) and light chain variable region of natural antibodies (VL)-linked (usually through a synthetic connecting peptide (or “linker”)) small molecule recombinant antibody.
  • VH heavy chain variable region
  • VL light chain variable region of natural antibodies
  • the scFv single-chain antibody Compared with the complete antibody molecule, the scFv single-chain antibody has the following advantages: it contains the complete antibody variable region and retains the antigen specificity and binding activity of the original antibody; it does not contain the Fc region of the antibody molecule, so it has weak immunogenicity and is used for The human body is not easy to produce an immune response; it is easy to operate and is suitable for use as a genetic engineering component to prepare other antigen-specific binding molecules with new properties, such as full-length antibodies, scFv-Fc, etc.
  • Fc region is used herein to define the C-terminal region of an immunoglobulin heavy chain, which region comprises at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • the human IgG heavy chain Fc region generally extends from Cys226 or Pro230 to the carbonyl terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as in Kabat et al., Sequences of Proteins of Immunological Interest, 5 th Ed. Public Health Service, As described in National Institutes of Health, Bethesda, MD, 1991.
  • knock into the hole refers to the creation of a "knob” structure on one Fc chain of the bispecific antibody molecule described in the present application, and a "hole” structure on the other chain, so that the hole and the knob have the same or similar size, suitably placed so that when two Fcs interact, the knob of one Fc can be positioned in the corresponding hole of the other Fc, thereby stabilizing the structure of the heteromultimer (see, e.g., U.S. Pat. No. 5,731,168 ).
  • knobs can be constructed by substituting smaller amino acid side chains with larger side chains, according to prior art techniques.
  • holes can be constructed by substituting large amino acid side chains with smaller side chains.
  • variable region refers to the domains of an antibody heavy or light chain that participate in the binding of the antibody to an antigen.
  • the variable domains of the heavy and light chains of native antibodies typically have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementarity determining regions (see, e.g., Kindt et al. Kuby Immunology, 6 th ed., WH Freeman and Co. p. 91 (2007)).
  • FRs conserved framework regions
  • a single VH or VL domain may be sufficient to confer antigen binding specificity.
  • CDR regions or “CDRs” or “hypervariable regions” are the highly variable in sequence and form structurally defined loops ("hypervariable loops") in antibody variable domains and and/or regions containing antigen contact residues ("antigen contact points").
  • the CDRs are primarily responsible for binding to antigenic epitopes.
  • the CDRs of the heavy and light chains are numbered sequentially from the N-terminus and are generally referred to as CDR1, CDR2 and CDR3.
  • the CDRs located within the variable domain of an antibody heavy chain are also referred to as HCDR1, HCDR2, and HCDR3, while the CDRs located within the variable domain of an antibody light chain are referred to as LCDR1, LCDR2, and LCDR3.
  • various schemes known in the art can be used to determine its CDR sequence, for example: Chothia( Chothia et al.
  • CDRs can also be determined based on having the same Kabat numbering position as the reference CDR sequence.
  • residue positions in antibody variable regions including heavy chain variable region residues and light chain variable region residues
  • Kabat numbering system Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
  • the boundaries of the CDRs of the variable region of the same antibody obtained based on different assignment systems may differ. That is, the CDR sequences of the variable region of the same antibody defined under different assignment systems are different.
  • the scope of said antibody also covers antibodies whose variable region sequences comprise said particular CDR sequence, but due to the application of a different protocol (e.g. Different assignment system rules or combinations) cause the claimed CDR boundary to be different from the specific CDR boundary defined in the present invention.
  • Antibodies with different specificities have different binding sites for different antigens.
  • CDRs vary from antibody to antibody, only a limited number of amino acid positions within a CDR are directly involved in antigen binding.
  • a minimal binding unit may be a subsection of a CDR.
  • the residues of the remainder of the CDR sequences can be determined from the structure and protein folding of the antibody. Accordingly, the invention also contemplates variations of any of the CDRs presented herein. For example, in a variant of a CDR, the amino acid residues of the smallest binding unit can remain unchanged, while the remaining CDR residues defined according to Kabat or Chothia can be replaced by conserved amino acid residues.
  • cytotoxic agent is used in the present invention to refer to a substance that inhibits or prevents cell function and/or causes cell death or destruction.
  • chemotherapeutic agent includes chemical compounds useful in the treatment of cancer.
  • small molecule drug refers to low molecular weight organic compounds capable of modulating biological processes.
  • Small molecules are defined as molecules having a molecular weight of less than 10 kD, usually less than 2 kD and preferably less than 1 kD.
  • Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptide mimetics, and antibody mimetics. As therapeutic agents, small molecules can be more cell permeable, less susceptible to degradation, and less prone to eliciting an immune response than larger molecules.
  • the term "functional Fc region” refers to an Fc region that possesses the "effector functions" of a native sequence Fc region.
  • exemplary “effector functions” include Clq binding; CDC; Fc receptor binding; ADCC; phagocytosis; Such effector functions generally require the association of an Fc region with a binding domain (eg, an antibody variable domain), and can be assessed using a variety of assays, such as those disclosed herein.
  • therapeutic agent encompasses any substance effective in the prevention or treatment of tumors, such as cancer, including chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, anti-infective agents, small molecule drugs, or immunomodulators .
  • the term "immunomodulator” refers to a natural or synthetic active agent or drug that suppresses or modulates an immune response.
  • the immune response can be a humoral or cellular response.
  • an effective amount refers to the amount or dosage of the antibody or its fragment or conjugate or composition of the present invention, which produces the desired effect in the patient in need of treatment or prevention after being administered to the patient in single or multiple doses.
  • “effective amount” can be divided into “therapeutic effective amount” and “prophylactic effective amount”.
  • An effective amount can be readily determined by the attending physician, who is skilled in the art, by considering various factors such as the species, size, age and general health of the mammal, the particular disease involved, the extent or severity of the disease, the individual patient response, the specific antibody administered, the mode of administration, the bioavailability characteristics of the formulation administered, the chosen dosing regimen, and the use of any concomitant therapy.
  • an effective amount of a bispecific antibody of the invention preferably inhibits a measurable parameter (eg, tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even compared to a control. More preferably at least about 50%, 60% or 70% and still more preferably at least about 80% or 90%.
  • a measurable parameter eg, tumor growth rate, tumor volume, etc.
  • host cell refers to a cell into which exogenous nucleic acid has been introduced, including the progeny of such a cell.
  • Host cells include “transformants” and “transformed cells,” which include the original primary transformed cell and progeny derived therefrom, regardless of the number of passages. Progeny may not be identical in nucleic acid content to the parental cell, but may contain mutations. Mutant progeny screened or selected for the same function or biological activity in originally transformed cells are included herein.
  • multispecific antibody refers to an antibody having at least two different antigen-binding sites, each of which is associated with a different epitope or Binds to different epitopes of different antigens.
  • Multispecific antibodies are antibodies that have binding specificities for at least two different antigenic epitopes.
  • bispecific antibodies that have binding specificities for a first antigen or target (CD79b) and a second antigen target (CD3).
  • CD79b first antigen or target
  • CD3 second antigen target
  • the antibody constructs according to the invention are (at least) bispecific, they are not naturally occurring and they differ significantly from naturally occurring products.
  • a "bispecific" antibody or immunoglobulin is an artificial hybrid antibody or immunoglobulin having at least two different binding sides with different specificities.
  • target means CD79b or CD3.
  • first target and second target means CD79b as the first target and CD3 as the second target or vice versa.
  • cytokine is a general term for proteins released by one cell population to act as intercellular mediators on another cell.
  • cytokines are lymphokines, monokines, interleukins (IL), such as IL-1, IL-1 ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL- 7.
  • the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of native sequence cytokines, including small molecular entities produced artificially, and their pharmaceutically acceptable derivatives and salts.
  • immunoconjugate is an antibody conjugated to one or more other substances, including but not limited to cytotoxic agents or labels.
  • mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., , mice and rats).
  • domesticated animals e.g., cattle, sheep, cats, dogs, and horses
  • primates e.g., humans and non-human primates such as monkeys
  • rabbits e.g., mice and rats
  • rodents e.g., mice and rats.
  • the individual or subject is a human.
  • isolated antibody is an antibody that has been separated from a component of its natural environment.
  • antibodies are purified to greater than 95% or 99% purity, such as by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase determined by HPLC).
  • electrophoresis e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography e.g., ion exchange or reversed-phase determined by HPLC.
  • the sequences are aligned for optimal comparison purposes (e.g., a first and second amino acid sequence or nucleic acid sequence may be placed between a first and a second amino acid sequence or nucleic acid sequence for optimal alignment). Gaps may be introduced in one or both or non-homologous sequences may be discarded for comparison purposes).
  • the length of the reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60% and even more preferably at least 70%, 80% , 90%, 100% of the reference sequence length.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the comparison of sequences and the calculation of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • the Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm (available at http://www.gcg.com available), use the Blossum 62 matrix or the PAM250 matrix with gap weights of 16, 14, 12, 10, 8, 6 or 4 and length weights of 1, 2, 3, 4, 5 or 6 to determine the distance between two amino acid sequences. percent identity.
  • using the GAP program in the GCG software package (available at http://www.gcg.com), using the NWSgapdna.CMP matrix and gap weights of 40, 50, 60, 70 or 80 and Length weights of 1, 2, 3, 4, 5 or 6 determine the percent identity between two nucleotide sequences.
  • a particularly preferred parameter set (and one that should be used unless otherwise stated) is the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
  • nucleic acid sequences and protein sequences described herein may further be used as "query sequences" to perform searches against public databases, eg, to identify other family member sequences or related sequences.
  • pharmaceutical excipient refers to a diluent, adjuvant (such as Freund's adjuvant (complete and incomplete)), excipient, carrier or stabilizer, etc., which are administered together with the active substance.
  • adjuvant such as Freund's adjuvant (complete and incomplete)
  • excipient carrier or stabilizer, etc.
  • composition refers to a composition that is present in a form that permits the biological activity of the active ingredients contained therein to be effective and that does not contain additional substances that are unacceptably toxic to the subject to which the composition is administered. ingredients.
  • combination therapy refers to the administration of two or more therapeutic agents to treat a cancer or an infection as described in this disclosure.
  • administration includes co-administration of the therapeutic agents in a substantially simultaneous manner, eg, in a single capsule with fixed ratios of the active ingredients.
  • administration includes co-administration for each active ingredient in multiple or in separate containers (eg tablets, capsules, powders and liquids). Powders and/or liquids can be reconstituted or diluted to the desired dosage before administration.
  • such administration also includes using each type of therapeutic agent in a sequential manner at about the same time or at different times. In either case, the treatment regimen will provide for the beneficial effect of the drug combination in treating the disorders or conditions described herein.
  • treating means slowing, interrupting, arresting, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease.
  • prevention includes the inhibition of the occurrence or development of a disease or disorder or a symptom of a particular disease or disorder.
  • subjects with a family history of cancer are candidates for prophylactic regimens.
  • prevention refers to the administration of a drug prior to the onset of signs or symptoms of cancer, particularly in subjects at risk of cancer.
  • vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it has been linked.
  • the term includes vectors that are self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors.”
  • CD79b, target CD79b, human CD79b refers to CD79b recombinant protein.
  • the extracellular domain of CD79b consists of amino acids 29-159 according to UniProt.
  • the "antibodies against CD79b” and “anti-CD79b antibodies” mentioned herein refer to antibodies that specifically bind to CD79b. .
  • an antibody that binds to CD79b has a dissociation constant (Kd) of 10 ⁇ 9 M or lower, preferably 10 ⁇ 9 M to 10 ⁇ 13 M.
  • the anti-CD79b antibody binds to an epitope of CD79b that is conserved in CD79b from different species, preferably in humans.
  • the "anti-CD79b antibody” described herein comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising CDRs from SEQ ID NO: 4, 14 or 24, the light chain can be The variable regions comprise CDRs from SEQ ID NO:9, 19 or 29.
  • T cells or T lymphocytes are a class of lymphocytes that play a central role in cell-mediated immunity.
  • the specificity of T cell responses is mediated by TCR recognition of antigens displayed in the context of the major histocompatibility complex MHC.
  • the CD3 receptor complex is a protein complex that includes a CD3 ⁇ (gamma) chain, a CD3 ⁇ (delta) chain, and two CD3 ⁇ (epsilon) chains present on the cell surface, involved in the activation of cytotoxic T cells ( CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
  • Clustering of CD3 on T cells such as by immobilized anti-CD3 antibodies, results in T cell activation similar to engagement of the T cell receptor but independent of its clonally specific specificity.
  • CD3 was found to be membrane bound to all mature T cells, and this high specificity, combined with the presence of CD3 at all stages of T cell development, makes it a useful immunohistochemical marker of T cells in tissue sections. It is envisaged that antibody constructs according to the invention generally and advantageously exhibit less non-specific T cell activation, which is not required in specific immunotherapy. This means a reduced risk of side effects.
  • an “anti-CD3 antibody” as referred to herein refers to an antibody that binds CD3.
  • an “anti-CD3 antibody” as described herein comprises a heavy chain variable region comprising the CDRs from SEQ ID NO: 34 or 44 and a light chain variable region comprising CDRs from SEQ ID NO: 39 or 49.
  • bispecific antibody that can bind to the target CD79b and CD3 with sufficient affinity, and the bispecific antibody can recruit T cells and perform redirected lysis on the target cells.
  • Engaged T cells are capable of continuous target cell lysis and are immune to immune escape mechanisms that interfere with peptide antigen processing and presentation or clonal T cell differentiation.
  • the "anti-CD79b and CD3 bispecific antibody” mentioned herein comprises a heavy chain variable region targeting CD79b and a light chain variable region
  • the heavy chain variable region comprises a sequence derived from SEQ ID NO:4 , CDRs of 14 or 24, the light chain variable region contains CDRs from SEQ ID NO: 9, 19 or 29, and the heavy chain variable region targeting CD3 and the light chain variable region, the heavy chain variable region contains CDRs from The CDRs of SEQ ID NO: 34 or 44, the light chain variable region comprises the CDRs from SEQ ID NO: 39 or 49.
  • the antibodies can be used as diagnostic and/or therapeutic agents targeting CD79b-expressing cancers.
  • the anti-CD79b ⁇ CD3 bispecific antibody provided by the present invention has the following advantages:
  • the anti-CD79b ⁇ CD3 bispecific antibody of the present invention is formed by assembling different anti-CD79b antibodies with anti-CD3 antibodies with different affinities, through the CD8+ induced by the anti-CD79b ⁇ CD3 bispecific antibody Introducing the detection of the activation degree of T cells and the release level of various cytokines in the killing experiment of T against tumor cells is beneficial to the early (in vitro screening stage) comprehensive evaluation of the efficacy and safety of CD79b/CD3 double antibody. Screening differentiated molecules with similar maximal kill and lower cytokine release levels in the in vitro screening stage for in vivo experiments and toxicology experiments will help reduce the risk of cytokine storms during the clinical application of such double antibodies.
  • the CD79b/CD3 double antibody of the present invention simultaneously binds to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells and CD3 on the surface of primary T cells to mediate the killing of CD79b-positive tumor cells by T cells.
  • the bispecific antibody of the present invention can dose-dependently induce the killing effect of CD8+T on B-cell non-Hodgkin's lymphoma cells with different CD79b expression levels.
  • the anti-CD79b ⁇ CD3 antibodies of the invention mediate killing of human B-cell non-Hodgkin's lymphoma cells and dose-dependently activate CD8+ T cells and CD4+ T cells isolated from PBMCs. In some embodiments, the antibodies of the invention promote the proliferative ability of human CD8+T, CD4+T cells.
  • the antibody of the present invention can effectively inhibit tumor growth, and the tumor inhibition rate can reach 67% or even 100% compared with the control.
  • anti-CD79b ⁇ CD3 bispecific antibodies with amino acid changes are covered herein, wherein said amino acid changes include amino acid substitutions, insertions or deletions.
  • amino acid changes described herein are amino acid substitutions, preferably conservative substitutions.
  • amino acid changes described herein occur in regions outside the CDRs (eg, in FRs). More preferably, the amino acid changes of the present invention occur in regions outside the heavy chain variable region and/or outside the light chain variable region.
  • substitutions are conservative substitutions.
  • a conservative substitution is one in which an amino acid is replaced by another within the same class, such as one acidic amino acid by another acidic amino acid, one basic amino acid by another basic amino acid, or one neutral amino acid by another neutral amino acid replacement. Exemplary permutations are shown in the table below:
  • substitutions occur in the CDR regions of the antibody.
  • the resulting variant is modified (eg, improved) relative to the parent antibody in certain biological properties (eg, increased affinity) and/or will have certain biological properties of the parent antibody that are substantially retained.
  • exemplary substitutional variants are affinity matured antibodies.
  • the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody is conveniently accomplished by altering the amino acid sequence to create or remove one or more glycosylation sites. When the antibody comprises an Fc region, the carbohydrate attached to it can be altered. In some applications, modifications to remove unwanted glycosylation sites may be useful, such as removal of fucose moieties to improve antibody-dependent cell-mediated cytotoxicity (ADCC) function (see Shield et al. (2002 )JBC277:26733). In other applications, galactosidation modifications can be made to modify complement dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • Fc region variants may include human Fc region sequences (eg, human IgGl, IgG2, IgG3 or IgG4 Fc regions) comprising amino acid modifications (eg, substitutions) at one or more amino acid positions.
  • human Fc region sequences eg, human IgGl, IgG2, IgG3 or IgG4 Fc regions
  • amino acid modifications eg, substitutions
  • Fc variants see US Patent No. 7,332,581, US Patent No. 6,737,056, US Patent No. 6,737,056; WO 2004/056312 and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001), USA Patent No. 6,194,551, WO99/51642 and Idusogie et al. J.
  • cysteine-engineered antibodies eg, "thioMAbs”
  • cysteine residues of the antibody are replaced with cysteine residues.
  • Cysteine engineered antibodies can be produced as described, eg, in US Pat. No. 7,521,541.
  • the antibodies provided herein can be further modified to contain other non-proteinaceous moieties known and readily available in the art.
  • Moieties suitable for antibody derivatization include, but are not limited to, water soluble polymers.
  • Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl -1,3-dioxane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyamino acid (homopolymer or random copolymer), and dextran or poly(n-ethylene pyrrolidone) polyethylene glycol, propylene glycol homopolymer, polypropylene oxide/ethylene oxide copolymer, polyoxyethylated polyols (such as glycerin), polyvinyl alcohol, and mixture
  • the invention provides nucleic acids encoding any of the above anti-CD79b, anti-CD3 and anti-CD79b ⁇ CD3 antibodies or antigen-binding fragments thereof.
  • the invention also encompasses nucleic acids that hybridize under stringent conditions to the aforementioned nucleic acids, nucleic acids that have one or more substitutions (e.g., conservative substitutions), deletions, or insertions compared to the aforementioned nucleic acids, or nucleic acids that have at least 80% of the aforementioned nucleic acids , at least 85%, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical nucleic acid sequences.
  • the present invention provides a vector comprising the nucleic acid described above.
  • the vector is an expression vector.
  • the invention provides a host cell comprising said nucleic acid or said vector.
  • Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells (eg, CHO cells or 293 cells), or other cells suitable for the production of antibodies or antigen-binding fragments thereof.
  • the invention provides a composition, preferably a pharmaceutical composition, comprising any of the anti-CD79b ⁇ CD3 antibodies or antigen-binding fragments thereof described herein.
  • the composition further comprises pharmaceutical excipients.
  • a composition e.g., a pharmaceutical composition
  • compositions of the present invention may also contain one or more other active ingredients as required for the particular indication being treated, preferably those active ingredients that do not adversely affect the activity of each other.
  • active ingredients such as chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, anti-infective agents, small molecule drugs, or immunomodulators, among others.
  • the active ingredients are suitably present in combination in amounts effective for the intended use.
  • the present invention designs a monospecific antibody targeting CD79b, which can bind to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells, based on five anti-CD79b antibodies (34F1, 11G10, 38D9, 54H6, 60D9), through Humanized 5 humanized anti-CD79b antibodies (hz34F1.14, hz11G10.9.p1, hz38D9B3.11, hz54H6A3.13, hz60D9H6.2)
  • Another aspect of the present invention is to design a T cell integrator (T-cell engager) bispecific antibody targeting both CD79b and CD3, which can simultaneously bind to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells and CD3 on the surface of T cells .
  • T-cell engager T cell integrator bispecific antibody targeting both CD79b and CD3, which can simultaneously bind to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells and CD3 on the surface of T cells .
  • the design targets both CD79b and CD3 bispecific antibody.
  • a total of 6 bispecific antibody molecules in 1+1 format were designed (38D9B3.11/sp34.87, 38D9B3.11/sp34.24, 11G10.9.p1/sp34.87, 11G10.9.p1/sp34.24, 34F1.14/sp34.87, 34F1.14/sp34.24.24).
  • Use Fc "knob-in-hole” technology to solve the heavy chain mismatch of bispecific antibodies Fc is the heavy chain constant region of IgG1, and introduce L234A, L235A ( Amino acid mutations according to Kabat's "EU” numbering).
  • Embodiment 1 the preparation of hybridoma cell
  • CD79b protein (sino, Cat#29750-H08H) was emulsified with complete Freund's adjuvant (sigma, Cat#F5881) to immunize Balb/c mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), two After one week, it was emulsified with Freund's incomplete adjuvant (sigma, Cat#F5506) and then immunized three times, and intramuscularly injected once every two weeks (50ug protein per mouse).
  • the spleen of the mouse is removed to prepare a suspension of B lymphocytes, which is mixed with SP2/0 myeloma cells (ATCC) at a ratio of 1:2 to 1:1 and then electrofused.
  • ATC SP2/0 myeloma cells
  • the selection medium was replaced on the 7th day after fusion, and flow cytometry (FACS) was performed on the 10th day of culture (or longer, depending on the state of cell growth) to screen for positive clones.
  • FACS flow cytometry
  • the hybridoma cells specifically expressing anti-CD79b antibody were screened by flow cytometry (FACS).
  • the cells to be detected (Ramos) were counted and diluted to 1 ⁇ 10 6 cells/ml, and 100 ⁇ l/well was added to a U-bottom 96-well plate. Centrifuge at 500g for 5min to remove the cell culture medium.
  • the hybridoma 96-well plate culture supernatant was added to a U-shaped plate and the cells were resuspended, adding 100 ⁇ l to each well, and left to stand on ice for 30 minutes. Centrifuge at 500g for 5 minutes to remove the supernatant, and wash the cells once with PBS.
  • Subcloning step prepare a 96-well plate, add 200 ⁇ l of medium to each well, and replace HAT with HT (Gibco, Cat#11067-030) on the basis of the screening medium, and the rest of the formula is the same.
  • Make a cell suspension from the cells in the positive wells screened out above take 100ul and add them to each well in the first row and mix well, then take 100 ⁇ l of the cell suspension in the first row and add it to the second row, mix well Then take 100 ⁇ l and add it to the next row; repeat the above steps, let the 96-well plate stand for 30 minutes, observe and count under the microscope. Take the volume corresponding to 100 cells and add 20ml of medium, mix well and plate, 200 ⁇ l per well.
  • the antibody light and heavy chain gene sequences were retrieved from the hybridoma candidate clones obtained in Example 1. Take about 5 ⁇ 10 6 freshly cultured cells per strain, and extract RNA (Macherey-Nagel, Cat#740984.250). cDNA was obtained by reverse transcription using PrimeScript II 1st Strand cDNA Synthesis Kit (Takara).
  • the upstream primer is designed with the base sequence located in the 5' end FR1 region
  • the downstream primer is designed with the base sequence located in the antibody constant region or FR4 region to amplify the antibody light chain and heavy chain variable region gene fragments.
  • the antibody is constructed by recombinant murine antibody.
  • the light and heavy chain variable region gene fragments were respectively passed through the homologous recombination enzyme (cat. No.: C112-01) was connected to the pcDNA3.1 vector, wherein IgG1 subtype was selected for the constant region, and expression plasmids for light chain and heavy chain antibodies were obtained.
  • the light chain plasmid and heavy chain plasmid of the same antibody were mixed at a molar ratio of 1:1, and transfected into 293F cells with polyethyleneimine (PEI) (Polysciences, Cat#23966). After 5-7 days of culture, the cell viability was low At 60%, the cell culture supernatant was collected and the monoclonal antibody was purified with Protein A affinity column.
  • PEI polyethyleneimine
  • Example 3 Determination of the binding kinetics of the chimeric antibody and antigen of the present invention by biomembrane thin layer interference technique
  • the equilibrium dissociation constant (KD) of the antibody of the present invention binding to CD79b was determined by biofilm thin layer interferometry technique (ForteBio). ForteBio affinity determination was carried out according to the existing method (Estep, P et al., High throughput solution Based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013.5 (2): p. 270-8).
  • the AMQ (Pall, 1506091) sensor was equilibrated offline for 30 minutes in assay buffer, followed by online detection for 60 seconds to establish a baseline, and the purified antibody obtained as described above was loaded online onto the AHQ sensor (ForteBio) for ForteBio Affinity measurement. The sensor with loaded antibody was then exposed to the antigen CD79b, after which the sensor was transferred to assay buffer for off-rate measurement. KD values were analyzed using ForteBio analysis software. The detection results of antibody affinity are shown in Table 2:
  • Example 4 Binding experiment of chimeric antibody and B-cell non-Hodgkin's lymphoma cell line
  • this study used flow cytometry to detect the binding of the antibody to Ramos and BJAB cells.
  • the experimental process is as follows:
  • Ramos ATCC, Cat. No. CRL-1596
  • BJAB US AddexBio, Cat. No. C0003016
  • the cells were cultured and passaged according to routine operations. After the cells were resuspended by centrifugation, the cells were counted, and the cell density was adjusted to 4X10 6 cell/ml, poured into the sample tank, and seeded in a 96-well plate at 50 ul per well with a row gun. Add 50ul of serially diluted antibody samples to each well of 50ul cells, and then place them in a cell culture incubator at 37°C with 5% CO2 for 30 minutes. Centrifuge at 400g for 5 minutes to spin the plate, add 200ul PBS 400g and spin the plate for 5 minutes, repeat 3 times.
  • the chimeric antibody obtained in Example 2 was humanized according to conventional methods.
  • humanized antibodies hz34F1.14, hz11G10.9.p1, hz38D9B3.11, hz54H6A3.13, hz60D6H6.2, its CDR sequence, light chain variable region and heavy chain variable region sequence, light chain and See Example 9 for the amino acid sequence of the heavy chain.
  • the equilibrium dissociation constant (KD) of the humanized antibody of the present invention binding to human CD79b was determined using a ForteBio assay. Assay method is the same as in Example 3, and the data are shown in Table 3.
  • the binding of humanized antibody to Ramos and BJAB cells was detected by flow cytometry.
  • the determination method is the same as that in Example 4.
  • the binding of the humanized antibody to CD79b on the surface of Ramos cells is shown in FIG. 3 ; the binding of the humanized antibody to CD79b on the surface of BJAB cells is shown in FIG. 4 .
  • ADCC effector cell Promega's Jurkat-ADCC NF-AT luciferase effector cell line
  • the target cells 293T-hCD79b and ADCC effector cells were counted. Centrifuge to remove the supernatant, wash the cells twice with PBS, resuspend with the detection medium (1640 medium (Gibco) with 5% low IgG serum), adjust the concentration of ADCC effector cells to 2 ⁇ 10 7 cells/ml, and adjust the concentration of target cells It was 2 ⁇ 10 6 cells/ml. The two kinds of cells were mixed according to 1:1, and the final effect-to-target ratio was 10:1.
  • Diluted antibody gradiently diluted antibody sample, the final concentration of the first well was 300nM, 4-fold dilution, a total of 10 gradients, 50ul of antibody was added to 50ul of cells in each well.
  • CD79b.A7v14b/38E4v1 is a CD79b/CD3 bispecific antibody from patent US20180327492, which is expressed by the same method.
  • the above 7 bispecific antibodies obtained are used in the following examples.
  • the specific amino acid sequence list (the CDR region is defined by the Kabat rule) is as follows:
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO: 1): GYTFTDYSMH;
  • HCDR2 (SEQ ID NO:2): WINTETGEPSYADDFKG;
  • HCDR3 (SEQ ID NO: 3): GPY;
  • Heavy chain variable region VH sequence (SEQ ID NO: 4):
  • LCDR1 (SEQ ID NO: 6): KASQSVDHDDVDSYMD;
  • LCDR2 (SEQ ID NO: 7): SASNLES;
  • LCDR3 (SEQ ID NO: 8): QQINEYPYT;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO: 11): GYTFTDYWVN;
  • HCDR2 (SEQ ID NO: 12): MIDPSDSETHYNQMFND;
  • HCDR3 (SEQ ID NO: 13): SNYY;
  • Heavy chain variable region VH sequence (SEQ ID NO: 14):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO: 16): KSSQSLLDSEGKTYLN;
  • LCDR2 (SEQ ID NO: 17): LVSKLDS;
  • LCDR3 (SEQ ID NO: 18): GTHFPLT;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO:21): GYSFTTYWMN;
  • HCDR2 (SEQ ID NO:22): MIDPSDSETHYNHLFKD;
  • HCDR3 (SEQ ID NO: 23): AIGY;
  • Heavy chain variable region VH sequence (SEQ ID NO:24):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO: 26): KSSLSLLDSEGKTYLN;
  • LCDR2 (SEQ ID NO: 27): LVSKLDS;
  • LCDR3 (SEQ ID NO: 28): WQGTHFPLT;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO: 31): GFTFNTYAMN;
  • HCDR2 (SEQ ID NO:32): RIRSKYNNYATYYAD;
  • HCDR3 (SEQ ID NO:33): HYNFGQSYVSWFAY;
  • Heavy chain variable region VH sequence (SEQ ID NO: 34):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO: 36): RSSTGAVTTSNYAN;
  • LCDR2 (SEQ ID NO:37): GTNKRAP;
  • LCDR3 (SEQ ID NO: 38): ALWYSNLWV;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO: 41): GFTFNTYAMN;
  • HCDR2 (SEQ ID NO: 42): RIRSKYNNYATYYADSVKD;
  • HCDR3 (SEQ ID NO:43): HGNFGQSYVSWFAY;
  • Heavy chain variable region VH sequence (SEQ ID NO: 44):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO: 46): RSSTGAVTTSNYAN;
  • LCDR2 (SEQ ID NO: 47): GTNKRAP;
  • LCDR3 (SEQ ID NO: 48): ALWYSNLWV;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO:51): GYTFTTYYMN;
  • HCDR2 (SEQ ID NO:52): MIDPSDSETHYNQKFQG;
  • HCDR3 (SEQ ID NO: 53): SLAF;
  • Heavy chain variable region VH sequence (SEQ ID NO:54):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO:56): KSSQSLLDSDGKTYLN;
  • LCDR2 (SEQ ID NO: 57): LVSKLDS;
  • LCDR3 (SEQ ID NO: 58): WQGTHFPQT;
  • the heavy chain CDR sequence is as follows:
  • HCDR1 (SEQ ID NO: 61): GFTFTSYYIH;
  • HCDR2 (SEQ ID NO:62): WIYPENDNTKYNEKFKD;
  • HCDR3 (SEQ ID NO:63): DGYSRYYFDY;
  • Heavy chain variable region VH sequence (SEQ ID NO:64):
  • the light chain CDR sequence is as follows:
  • LCDR1 (SEQ ID NO:66): KSSQSLLNSRTRKNYLA;
  • LCDR2 (SEQ ID NO: 67): WTS STRKS;
  • LCDR3 (SEQ ID NO: 68): KQSFILRT;
  • the human CD79b-His antigen was diluted in 10mM Acetate (pH 5.0), and the concentration was diluted to 1 ⁇ g/mL, and about 50RU was coupled. The remaining activated sites were then blocked by injecting 1M ethanolamine at a flow rate of 10 ⁇ L/min for 420 s.
  • the buffer used in the experiment was HBS-EP+ solution with pH 7.4, and the high performance mode was used to measure a 2-fold serially diluted antibody (0-80nM) from low concentration to high concentration at a flow rate of 30 ⁇ l/min for each cycle.
  • the concentration is injected into the 1, 2, 3, and 4 channels of the chip in sequence, the binding time is 180s, and the dissociation time is 600s.
  • the 2-fold diluted antibody (0-16nM or 0-40nM or 0-200nM), from low concentration to high concentration at a flow rate of 30 ⁇ l/min, measures a concentration for each cycle, and injects it into the chip in turn1,2,3 , 4 channels, combined time 180s, dissociation time 300s.
  • Example 11 Binding experiment of anti-CD79b/CD3 antibody of the present invention to B-cell non-Hodgkin's lymphoma cell line
  • CD79b/CD3 bispecific antibody to CD79b-positive B-cell non-Hodgkin's lymphoma cell line was detected by flow cytometry.
  • BJAB (AddexBio, USA, product number C0003016) and WSU-DLCL2 (Nanjing Kebai Biotechnology, product number CBP60273) were cultured and passaged according to routine operations. After the cells were resuspended by centrifugation, the cells were counted, and the cell density was adjusted to 4X10 6 cell/ml, poured into the sample tank, and seeded in a 96-well plate at 50 ul per well with a row gun. Add 50ul of serially diluted antibody samples to each well of 50ul cells, and then place them in a cell culture incubator at 37°C with 5% CO2 for 30 minutes.
  • Example antibodies bound to CD79b on the surface of the CD79b high expressing cell line BJAB cells are shown in Figure 6; exemplary antibodies bound to CD79b on the surface of the CD79b low expressing cell line WSU-DLCL2 cells were shown in Figure 7 in experiments performed as described in the assay above.
  • Example 12 Activation experiment of anti-CD79b/CD3 antibody of the present invention on Jurkat-NFAT-Luc cells
  • the CD79b/CD3 double antibody simultaneously binds to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells and CD3 on the surface of Jurkat-NFAT-Luc cells, and activates the downstream signaling pathway of NFAT-Luc through CD79b-dependent CD3 cross-linking.
  • the luciferase reporter gene method was used to detect the co-culture of Jurkat-NFAT-Luc cells and CD79b-positive cells, and the expression of luciferase after overnight incubation with the example antibody was used to reflect the activation ability of the antibody.
  • Assay medium preparation 10% FBS+90% RPMI Medium 1640
  • Bio-Glo Luciferase Assay System detection solution Melt Bio-Glo TM buffer (Promega, G7940), add Bio-Glo TM substrate (Promega, G7940), mix well, and store in a -40°C refrigerator.
  • step 4 Take out the samples incubated in step 2, and add 80 ⁇ L of Bio-Glo Luciferase Assay System detection solution to each well.
  • Microplate reader (Molecular Device, SpectraMax I3) reading.
  • the exemplary antibodies were able to dose-dependently activate NFAT signaling (see Figures 8A, 8B), the exemplary antibodies showed no activation of NUGC4 on non-target cells (see Figure 8C).
  • Example 13 Killing experiment of anti-CD79b/CD3 antibody of the present invention on B-cell non-Hodgkin's lymphoma cell line
  • the CD79b/CD3 double antibody simultaneously binds to CD79b on the surface of B-cell non-Hodgkin's lymphoma cells and CD3 on the surface of primary T cells, activates T cells through CD79b-dependent CD3 cross-linking, and mediates T cells against CD79b-positive tumors cell killing.
  • the Propidium Iodide staining (PI) method was used to detect the PI-positive ratio of human CD8+ T cells and CD79b-positive cells under the co-culture condition of human CD8+ T cells and CD79b-positive cells, and the PI-positive tumor cells were added for 48 hours to evaluate the effect of human CD8+ T cells on CD79b-positive tumors. cell killing ability.
  • the PBMCs were taken out from the liquid nitrogen tank and melted rapidly at 37° C., and added dropwise to preheated 1640 medium (containing 0.1% DNase) containing 10% FBS to obtain 10 ml of a mixed solution. Centrifuge at 400 g for 5 minutes, resuspend with 10 ml of 1640 medium containing 10% FBS, add 10 ⁇ l of DNase, and let stand for 2 hours at 37°C and 5% CO2.
  • Human CD8+ T cells were isolated using the EasySep TM Human CD8+ T Cell Enrichment Kit and used according to the instructions. Use 1640 medium containing 10% FBS to adjust the density of human CD8+ T cells to 1 ⁇ 10 6 cells/ml as effector cells.
  • CD79b positive cells BJAB and WSU-DLCL2 were used as target cells, NUGC4 was used as non-target cells, centrifuged at 400g for 5 minutes, resuspended in 1640 medium containing 10% FBS, added CellTrace Far Red Cell staining solution (THERMO FISHER, C34564) and incubated for 30 minutes, centrifuge at 400g for 5 minutes, resuspend with 1640 medium containing 10% FBS, and adjust the cell density to 2 ⁇ 10 5 cell/ml. Mix the tumor cell and human CD8+ T cell suspension at a ratio of 1:1, take a (public) 96-well round-bottom culture plate (with a cover), add 200 ⁇ l of cell suspension and serially diluted antibody to be tested to each well.
  • THERMO FISHER CellTrace Far Red Cell staining solution
  • the exemplary antibodies were able to induce dose-dependent killing of human CD8+ T cells on BJAB and WSU-DLCL2 target cells (see Figure 9A, 9B), and the exemplary antibodies were able to induce killing of non-target cells in a dose-dependent manner.
  • NUGC4 showed no killing effect (see Figure 9C).
  • Example 14 Accompanying T cell activation and cytokine release levels during the killing process of the anti-CD79b/CD3 antibody of the present invention on human B-cell non-Hodgkin's lymphoma cell lines
  • example antibodies were added to the co-incubation system of B cell non-Hodgkin's lymphoma cell lines and human T cells. After 18 hours, the percentage of CD25 and CD69 double positive cells of human T cells was detected by flow cytometry to evaluate Antibody-mediated activation of T cells in the co-incubation system of human T cells and CD79b-positive tumor cells.
  • a multifactor detection kit Human Th1/Th2/Th17, BD was used to simultaneously detect the levels of multiple cytokines to evaluate the ability of T cells to release cytokines in the co-incubation system of antibody-mediated human T cells and CD79b-positive tumor cells.
  • the PBMCs were taken out from the liquid nitrogen tank and melted rapidly at 37° C., and added dropwise to preheated 1640 medium (containing 0.1% DNase) containing 10% FBS to obtain 10 ml of a mixed solution. Centrifuge at 400 g for 5 minutes, resuspend with 10 ml of 1640 medium containing 10% FBS, add 10 ⁇ l of DNase, and let stand for 2 hours at 37°C and 5% CO2.
  • Human CD8+ T cells were isolated using the EasySep TM Human CD8+ T Cell Enrichment Kit and used according to the instructions.
  • the PBMCs were taken out from the liquid nitrogen tank and melted rapidly at 37° C., and added dropwise to preheated 1640 medium (containing 0.1% DNase) containing 10% FBS to obtain 10 ml of a mixed solution. Centrifuge at 400 g for 5 minutes, resuspend with 10 ml of 1640 medium containing 10% FBS, add 10 ⁇ l of DNase, and let stand for 2 hours at 37°C and 5% CO2.
  • Human CD4+ T cells were isolated using the EasySep TM Human CD4+ T Cell Enrichment Kit and used according to the instructions.
  • the degree of CD8+ activation accompanying CD8+ T killing of BJAB cells induced by an exemplary antibody is shown in Figure 10A;
  • the degree of activation is shown in Figure 10B;
  • the degree of CD8+ activation accompanied by the killing process of CD8+ T cells induced by an example antibody against WSU-DLCL2 cells is shown in Figure 10C;
  • the degree of CD8+ activation accompanied by the killing process of CD8+ T cells induced by an example antibody against NUGC4 cells is shown in Figure 10D.
  • the release level of IFN- ⁇ accompanying the killing process of CD8+T cells induced by an example antibody is shown in Figure 11; the release level of TNF ⁇ accompanying the killing process of CD8+T cells induced by an example antibody is shown in Figure 12.
  • the degree of CD4+ activation accompanied by the co-incubation process of CD4+ T and BJAB cells induced by an example antibody is shown in Figure 13A;
  • the degree of CD4+ activation accompanied by the co-incubation process of T and WSU-DLCL2 cells is shown in Figure 13C;
  • the exemplary antibodies can dose-dependently activate CD8+T and CD4+T cells isolated from PBMCs, and there is a certain correlation between the degree of activation of T cells and the affinity of CD3: Anti-CD3 The higher the affinity, the stronger the ability to activate T cells.
  • Example 15 Experiments illustrating the ability of antibodies to promote the proliferation of human CD8+ T cells
  • Isolation of human CD8+ T cells Take out PBMC from the liquid nitrogen tank and thaw quickly at 37°C, slowly add the cells to 10ml of 1640 medium containing 10% FBS at 37°C (containing 0.1% DNase), 300g, 8 minutes , centrifuged at 25°C, removed the supernatant, resuspended in T75 with 10% FBS 1640 medium at 37°C (containing 0.1% DNase) and placed in a 5% CO2 incubator at 37°C for 3 hours.
  • Human CD8+ T cells were isolated using the EasySep TM Human CD8+ T Cell Enrichment Kit and used according to the instructions.
  • the exemplified antibodies were effective in stimulating CD8+ T cell proliferation in vitro in the presence of CD79b-positive cells (see Figures 14A, 914 and 14C); whereas in the presence of CD79b-negative NUGC4 cells When , the example antibody had no CD79b-independent non-specific proliferation of CD8+ T cells (see FIG. 14D ).
  • Example 16 Experiments illustrating the ability of antibodies to promote the proliferation of human CD4+ T cells
  • Exemplary antibodies can dose-dependently stimulate the proliferation of human CD4+ T cells in vitro in the presence of CD79b-positive tumor cells. However, in the presence of CD79b-negative NUGC4 cells, the exemplary antibody does not have CD79b-independent nonspecific proliferation of human CD4+ T cells.
  • Isolation of human CD4+ T cells take out PBMC from the liquid nitrogen tank and thaw quickly at 37°C, slowly add the cells to 10ml of 1640 medium containing 10% FBS at 37°C (containing 0.1% DNase), 300g, 8 minutes , centrifuged at 25°C, removed the supernatant, resuspended in T75 with 10% FBS 1640 medium at 37°C (containing 0.1% DNase) and placed in a 5% CO2 incubator at 37°C for 3 hours.
  • Human CD4+ T cells were isolated using the EasySep TM Human CD4+ T Cell Enrichment Kit and used according to the instructions.
  • the exemplified antibodies were effective in stimulating CD4+ T cell proliferation in vitro in the presence of CD79b-positive cells (see Figures 15A, 15B, and 15C); whereas in the presence of CD79b-negative NUGC4 cells When , the exemplary antibody did not have CD79b-independent non-specific proliferation of CD4+ T cells (15D).
  • Example 17 In vivo efficacy test of anti-CD79b/CD3 antibody of the present invention in animals
  • the human B-cell non-Hodgkin's lymphoma cell line WSU-DLCl2 and Ramos cells were used to inoculate the PBMC model of NOG mice to determine the anti-tumor effect of the exemplary antibodies.
  • mice 14-17 g were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The grade is SPF grade. Mice were acclimatized and quarantined for 7 days upon arrival prior to initiation of the study.
  • mice were intravenously injected with PBMC cells, 4x106 /mouse, and the inoculation volume was 200ul/mouse.
  • WSU-DLCL2 cells were inoculated on the third day after PBMC injection.
  • the WSU-DLCL2 cells were routinely subcultured, collected by centrifugation, dispersed with PBS, and inoculated with WSU-DLCL2 cells by shaved hair on the right dorsal and abdomen of NOG mice, 6x106 cells/mouse, inoculation volume 200ul/mouse.
  • Body weight was measured using an electronic balance. Mice were euthanized when tumors reached endpoint or when mice had >20% body weight loss throughout the study period. The tumor size was counted, and the tumor inhibition rate (TGI%) was calculated.
  • the tumor growth curve is shown in Figure 16.
  • An example antibody can significantly inhibit the growth of WSU-DLCL2 cells.
  • the tumor size was counted on day 22, and the tumor inhibition rate was calculated.
  • the tumor inhibition rates of exemplary antibodies 38D9B3.11/sp34.87, 38D9B3.11/sp34.24 and 11G10.9.p1/sp34.24 were 78%, 93% and 67%, respectively.
  • the TGI of CD79b.A7v14b/38E4v1 was only 36%. At the same time, no significant weight loss was found in the administered mouse groups.
  • mice 14-17 g were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The grade is SPF grade, and the mice are acclimatized and quarantined for 7 days after arrival, and then start the study.
  • PBMC cells Resuscitate the PBMC cells with RPMI-1640 medium preheated with 0.1% DNase, and then disperse the PBMC cells with PBS to prepare a cell suspension with a cell concentration of 20 ⁇ 10 6 cells/mL.
  • Mice were intravenously injected with PBMC cell suspension, 0.2 mL/mouse, that is, the inoculum volume was 4 ⁇ 10 6 cells/mouse.
  • Ramos cells were routinely subcultured for subsequent in vivo experiments. Seven days after the PBMC cells were inoculated, the Ramos cells were dispersed with PBS and Matrigel at a ratio of 1:1 to prepare a cell suspension with a cell concentration of 7.5 ⁇ 10 6 cells/mL. The right back of NOG mice was shaved, and the Ramos cell suspension was injected subcutaneously, 0.2 mL/mouse, that is, the inoculation volume was 1.5 ⁇ 10 6 cells/mouse.
  • mice Six days after tumor cell inoculation, the mice were grouped according to tumor volume (6 mice in each group) and administered once every 3-4 days for 4 consecutive administrations.
  • the administration method is intraperitoneal injection, and the administration volume is 10ml/kg/time.
  • the tumor volume and body weight of the mice were monitored twice a week until the end of 20 days.
  • Tumor volume measurement: the maximum long axis (L) and maximum width axis (W) of the tumor were measured with a vernier caliper, and the tumor volume was calculated according to the following formula: V L ⁇ W2/2. Body weight was measured using an electronic balance.
  • the tumor growth curve is shown in Figure 17.
  • An example antibody can significantly inhibit the growth of Ramos.
  • the tumor size was counted on the 20th day, and the tumor inhibition rate was calculated.
  • the tumor inhibition rates of exemplary antibodies 38D9B3.11/sp34.87, 38D9B3.11/sp34.24 and 11G10.9.p1/sp34.24 were 76%, 90% and 100%, respectively.
  • the TGI of CD79b.A7v14b/38E4v1 was similar to 38D9B3.11/sp34.87, 77%. At the same time, no significant weight loss was found in the administered mouse groups.
  • Example 18 PK test of anti-CD79b/CD3 antibody of the present invention in animals
  • mice Female Balb/C mice were injected with 10 mg/kg of 38D9B3.11/sp34.87, 38D9B3.11/sp34.24 and 11G10.9.p1/sp34.24 by tail vein administration to study Its pharmacokinetic properties in mice. Blood was collected from the eyeballs of the mice at 0.083hr, 0.5hr, 2hr, 6hr, 24hr, 48hr, 4day, 7day, 14day and 21day after administration, and the blood was centrifuged at 3000rpm at 4°C for 10min to collect serum.
  • the antibody content in serum was measured by ELISA, and the half-life of 38D9B3.11/sp34.87, 38D9B3.11/sp34.24 and 11G10.9.p1/sp34.24 in mice was calculated.
  • the experimental results are shown in Figure 18.
  • the half-lives of 38D9B3.11/sp34.87, 38D9B3.11/sp34.24 and 11G10.9.p1/sp34.24 in mice were 10.4 days, 7.3 days and 7.0 days respectively. All have similar PKs to normal monoclonal antibodies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

提供特异性结合CD79b的抗体、特异性结合CD79b和CD3的双特异性抗体、编码所述抗CD79b抗体以及抗CD79b×CD3双特异性抗体的核酸、包含所述核酸的载体、包含所述核酸或载体的宿主细胞、包含所述抗体或其抗原结合片段的药物组合物。

Description

抗CD79b×CD3双特异性抗体及其用途 技术领域
本发明总体上涉及免疫学和抗体工程领域。具体而言，本发明涉及CD79b单特异性抗体及特异性结合CD79b和CD3的新型双特异性抗体。此外，本发明涉及编码所述抗体的核酸、包含所述核酸的载体、包含所述核酸或载体的宿主细胞、包含所述抗体或其抗原结合片段的药物组合物。此外，本发明涉及这些抗体、药物组合物等在疾病的免疫治疗、预防和/或诊断上的应用。
背景技术
CD79b隶属于免疫球蛋白超家族，和CD79a形成异源二聚体，两者和表面球蛋白一起构成BCR受体复合物。BCR本身没有传递信号的结构域，一旦有抗原和BCR结合，CD79a/b异源二聚体负责向下游传导信号，对维持整个B细胞的功能至关重要。研究显示，敲除CD79b后B细胞会限制在pre-B的阶段，无法进一步发育成熟。
非霍奇金淋巴瘤(NHL)约85％属于B-cell NHL，针对B-cell NHL的一线治疗复发率高(DLBCL一线治疗复发率30-40％)，复发病人预后差(DLBCL平均9-12月的OS)，后期疗法有限。同时每年新发病和复发难治病人数目庞大(中国和美国每年均有8万左右新发患者)，尤其是中国，每年死亡人数达到约5万人，是美国的2倍多。针对CD79b的抗体偶联药物已经在临床上对NHL病人显示出一定的疗效，但是仍有一部分病人对之产生耐药，且病人对于NHL的改良疗法仍然存在很大的未被满足的需求。
最近几年，基于双特异性抗体的免疫疗法取得了飞快的发展，它们能够同时结合细胞毒性细胞和肿瘤细胞上的表面抗原，介导细胞毒性细胞对肿瘤细胞的杀伤。和抗体偶联药物相比，在药效及安全性上可具有一定的优势。
本发明通过提供以高靶点特异性和高亲合力结合CD79b和CD3的双特异性抗体，尤其是通过与肿瘤细胞表面上表达的CD79b结合而使得T细胞可以募集到肿瘤细胞周围的双特异性抗体，满足了这方面的需求。
发明内容
本发明一方面涉及一种新的结合CD79b的抗体或其抗原结合片段。
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中，
1)所述VH包含SEQ ID NO:4所示的VH中所含的三个互补决定区域(CDR)HCDR1、HCDR2和HCDR3，并且所述VL包含SEQ ID NO:9所示的VL中所含的LCDR1、LCDR2和LCDR3；
2)所述VH包含SEQ ID NO:14所示的VH中所含的三个互补决定区域(CDR)HCDR1、HCDR2和HCDR3，并且所述VL包含SEQ ID NO:19所示的VL中所含的LCDR1、LCDR2和LCDR3；
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中，
(i)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1或SEQ ID NO:11所示的氨基酸序列；HCDR2包含SEQ ID NO:2或SEQ ID NO:12所示的氨基酸序列； HCDR3包含SEQ ID NO:3或SEQ ID NO:13所示的氨基酸序列；
和/或
(ii)其中所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6或SEQ ID NO:16所示的氨基酸序列；LCDR2包含SEQ ID NO:7或SEQ ID NO:17所示的氨基酸序列；LCDR3包含SEQ ID NO:8或SEQ ID NO:18所示的氨基酸序列。
在一些实施方案中，本发明提供了结合XXX的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中
1)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1所示的氨基酸序列；HCDR2包含SEQ ID NO:2所示的氨基酸序列；HCDR3包含SEQ ID NO:3所示的氨基酸序列；所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6所示的氨基酸序列；LCDR2包含SEQ ID NO:7所示的氨基酸序列；LCDR3包含SEQ ID NO:8所示的氨基酸序列；
2)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11所示的氨基酸序列；HCDR2包含SEQ ID NO:12所示的氨基酸序列；HCDR3包含SEQ ID NO:13所示的氨基酸序列；所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16所示的氨基酸序列；LCDR2包含SEQ ID NO:17所示的氨基酸序列；LCDR3包含SEQ ID NO:18所示的氨基酸序列；
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中，
(a)重链可变区VH
(i)包含与SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由其组成；或者
(ii)包含SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列或由其组成；或者
(iii)包含与SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列相比具有1个或多个(优选不超过10个，更优选不超过5、4、3、2、1个)的氨基酸改变(优选氨基酸置换，更优选氨基酸保守置换)的氨基酸序列，优选地，所述氨基酸改变不发生在CDR区中；
和/或
(b)轻链可变区VL
(i)包含与SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由其组成；
(ii)包含SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列或由其组成；或者
(iii)包含与SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列相比具有1个或多个(优选不超过10个，更优选不超过5、4、3、2、1个)的氨基酸改变(优选氨基酸置换，更优选氨基酸保守置换)的氨基 酸序列，优选地，所述氨基酸改变不发生在CDR区中。
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含
1)包含与SEQ ID NO:4所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的重链可变区VH，和包含与SEQ ID NO:9所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的轻链可变区VL；
2)包含与SEQ ID NO:14所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的重链可变区VH，和包含与SEQ ID NO:19所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的轻链可变区VL；
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含
1)包含SEQ ID NO:4所示的氨基酸序列的重链可变区VH和包含SEQ ID NO:14所示的氨基酸序列的轻链可变区VL；
2)包含SEQ ID NO:9所示的氨基酸序列的重链可变区VH和包含SEQ ID NO:19所示的氨基酸序列的轻链可变区VL；
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含重链和/或轻链，其中
(a)重链
(i)包含与SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由其组成；
(ii)包含SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列或由其组成；或者
(iii)包含与SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列相比具有1个或多个(优选不超过20个或10个，更优选不超过5、4、3、2、1个)的氨基酸改变(优选氨基酸置换，更优选氨基酸保守置换)的氨基酸序列，优选地，所述氨基酸改变不发生在重链的CDR区中，更优选地，所述氨基酸改变不发生在重链可变区中；
和/或
(b)轻链
(i)包含与SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由其组成；
(ii)包含SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列或由其组成；或者
(iii)包含与SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列相比具有1个或多个(优选不超过20个或10个，更优选不超过5、4、3、2、1个)的氨基酸改变(优选氨基酸置换，更优选氨基酸保守置换)的氨基酸序列，优选地，所述氨基酸改变不发生在轻链的CDR区中，更优选地，所述氨基酸改变不发生在轻链可变区中。
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含
1)包含与SEQ ID NO:5所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的重链，和包含与SEQ ID NO:10所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的轻链；
2)包含与SEQ ID NO:15所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的重链，和包含与SEQ ID NO:20所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列的轻链；
在一些实施方案中，本发明提供了结合CD79b的抗体或其抗原结合片段，其包含
1)包含SEQ ID NO:5所示的氨基酸序列的重链和包含SEQ ID NO:10所示的氨基酸序列的轻链；
2)包含SEQ ID NO:15所示的氨基酸序列的重链和包含SEQ ID NO:20所示的氨基酸序列的轻链；
在一些实施方案中，本发明提供了编码本发明结合CD79b的抗体或其抗原结合片段的分离的核酸，包含所述核酸的载体，包含所述核酸或所述载体的宿主细胞。
在一些实施方案中，本发明提供了制备本发明结合CD79b的抗体或其抗原结合片段的方法，所述方法包括在适于表达编码本发明所述的核酸的条件下培养本发明所述的宿主细胞。
在一些实施方案中，本发明提供了包含本发明结合CD79b的抗体或其抗原结合片段的免疫缀合物和药物组合物。
在一些实施方案中，本发明还提供了利用本发明结合CD79b的抗体或其抗原结合片段、免疫缀合物或药物组合物在制备用于预防和/或治疗肿瘤的药物中的应用。
在一些实施方案中，本发明还提供了预防和/或治疗肿瘤的方法，所述方法包括向受试者施用有效量的本发明结合CD79b的抗体或其抗原结合片段、免疫缀合物或药物组合物。
本发明还涉及检测样品中CD79b的方法，所述方法包括(a)本发明所述的抗体或其抗原结合片段接触；以及(b)检测抗体或其抗原结合片段与CD79b间的复合物的形成。
本发明另一方面还公开了一种新的同时靶向CD79b和CD3的双特异性抗体、编码所述双特异性抗体的多核苷酸、包含所述多核苷酸的载体、包含所述多核苷酸或载体的宿主细胞、以及所述双特异性抗体在个体中治疗、预防和/或诊断与CD79b活性相关的疾病中的用途。
因此，在一个方面，本发明提供了特异性结合CD79b且结合CD3的双特异性抗体(抗CD79b×CD3双特异性抗体)，其包含(i)抗CD79b抗体或其片段，和(ii)抗CD3抗体或其片段。在一个实施方案中，本发明提供了1+1格式的抗CD79b×CD3双特异性抗体，其由左右对称的四条多肽链组成，其中左半部分由第一轻链和第一重链组成，右半部分由第二重链和第二轻链组成，第一轻链和第一重链分别是靶向CD79b或CD3的抗体重链和轻链，第二重链和第二轻链分别是由靶向CD3或CD79b的抗体重链和轻链。
在一个实施方案中，本发明提供了1+1格式的抗CD79b×CD3双特异性抗体，其中第一轻链和第一重链特异性结合CD79b，第二重链和第二轻链特异性结合CD3。在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中第一轻链包含选自SEQ ID NO:9，19或29所包含的3个轻链CDR，第一重链包含选自SEQ ID NO:4，14或24所包含的3个重链 CDR，第二重链包含选自SEQ ID NO:34或44所包含的3个重链CDR，第二轻链包含选自SEQ ID NO:39或49所包含的3个轻链CDR。
在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，第一轻链和第一重链结合CD79b，第二重链和第二轻链结合CD3，其中:
1)第一轻链包含来自SEQ ID NO:9所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:4所包含的3个重链CDR，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR；
2)第一轻链包含来自SEQ ID NO:9所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:4所包含的3个重链CDR，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR；
3)第一轻链包含来自SEQ ID NO:19所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:14所包含的3个重链CDR，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR；
4)第一轻链包含来自SEQ ID NO:19所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:14所包含的3个重链CDR，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR；
5)第一轻链包含来自SEQ ID NO:29所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:24所包含的3个重链CDR，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR；或
6)第一轻链包含来自SEQ ID NO:29所包含的3个轻链CDR，第一重链包含来自SEQ ID NO:24所包含的3个重链CDR，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR。
在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中第一轻链包含选自SEQ ID NO:9，19或29所包含的3个轻链CDR且与SEQ ID NO:9，19或29具有至少90％同一性的VL，第一重链包含选自SEQ ID NO:4，14或24所包含的3个重链CDR且与SEQ ID NO:4，14或24具有至少90％同一性的VH，第二重链包含选自SEQ ID NO:34或44所包含的3个重链CDR且与SEQ ID NO:34或44具有至少90％同一性的VH，第二轻链包含选自SEQ ID NO:39或49所包含的3个轻链CDR且与SEQ ID NO:39或49具有至少90％同一性的VL。
在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中:
1)第一轻链包含来自SEQ ID NO:9所包含的3个轻链CDR且与SEQ ID NO:9具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:4所包含的3个轻链CDR且与SEQ ID NO:4具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR且与SEQ ID NO:34具 有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR且与SEQ ID NO:39具有至少90％同一性的VL；
2)第一轻链包含来自SEQ ID NO:9所包含的3个轻链CDR且与SEQ ID NO:9具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:4所包含的3个轻链CDR且与SEQ ID NO:4具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR且与SEQ ID NO:44具有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR且与SEQ ID NO:49具有至少90％同一性的VL；
3)第一轻链包含来自SEQ ID NO:19所包含的3个轻链CDR且与SEQ ID NO:19具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:14所包含的3个轻链CDR且与SEQ ID NO:14具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR且与SEQ ID NO:34具有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR且与SEQ ID NO:39具有至少90％同一性的VL；
4)第一轻链包含来自SEQ ID NO:19所包含的3个轻链CDR且与SEQ ID NO:19具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:14所包含的3个轻链CDR且与SEQ ID NO:14具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR且与SEQ ID NO:44具有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR且与SEQ ID NO:49具有至少90％同一性的VL；
5)第一轻链包含来自SEQ ID NO:29所包含的3个轻链CDR且与SEQ ID NO:29具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:24所包含的3个轻链CDR且与SEQ ID NO:24具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:34所包含的3个重链CDR且与SEQ ID NO:34具有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:39所包含的3个轻链CDR且与SEQ ID NO:39具有至少90％同一性的VL；或
6)第一轻链包含来自SEQ ID NO:29所包含的3个轻链CDR且与SEQ ID NO:29具有至少90％同一性的VL，第一重链包含来自SEQ ID NO:24所包含的3个轻链CDR且与SEQ ID NO:24具有至少90％同一性的VH，第二重链包含来自SEQ ID NO:44所包含的3个重链CDR且与SEQ ID NO:44具有至少90％同一性的VH，第二轻链包含来自SEQ ID NO:49所包含的3个轻链CDR且与SEQ ID NO:49具有至少90％同一性的VL。
在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中:
1)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:7的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:8的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1的氨基酸序列或由所述氨基酸序列组成， HCDR2包含SEQ ID NO:2的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:3的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
2)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:7的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:8的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:2的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:3的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成；
3)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:17的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:18的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:12的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:13的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
4)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16的氨基酸序列或 由所述氨基酸序列组成，LCDR2包含SEQ ID NO:17的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:18的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:12的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:13的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成；
5)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:26的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:27的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:28的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:21的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:22的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:23的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
或
6)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:26的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:27的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:28的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:21的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:22的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:23的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ  ID NO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成。
在另一个实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中第一轻链包含选自SEQ ID NO:9，19或29所示的VL，第一重链包含选自SEQ ID NO:4，14或24所示的VH，第二重链包含选自SEQ ID NO:34或44所示的VH，第二轻链包含选自SEQ ID NO:39或49所示的VL。
在一个具体的实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中:
1)第一轻链包含SEQ ID NO:9所示VL，第一重链包含SEQ ID NO:4所示VH，第二重链包含SEQ ID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；
2)第一轻链包含SEQ ID NO:9所示VL，第一重链包含SEQ ID NO:4所示VH，第二重链包含SEQ ID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL；
3)第一轻链包含SEQ ID NO:19所示VL，第一重链包含SEQ ID NO:14所示VH，第二重链包含SEQ ID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；
4)第一轻链包含SEQ ID NO:19所示VL，第一重链包含SEQ ID NO:14所示VH，第二重链包含SEQ ID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL；
5)第一轻链包含SEQ ID NO:29所示VL，第一重链包含SEQ ID NO:24所示VH，第二重链包含SEQ ID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；或
6)第一轻链包含SEQ ID NO:29所示VL，第一重链包含SEQ ID NO:24所示VH，第二重链包含SEQ ID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL。
在另一个实施方案中，本发明提供的抗CD79b×CD3双特异性抗体包含第一轻链、第一重链、第二重链和第二轻链，其中第一重链和第二重链包含相同或者不同的Fc区。在另一个优选的实施方案中，第一重链和第二重链所包含的Fc区分别具有“杵”和“臼”结构，所述杵臼结构相互作用从而稳定双特异性抗体的空间结构。
在一个具体实施方案中，在本发明的抗CD79b×CD3双特异性抗体中，第一重链和第二重链中包含的可变区与Fc区是同源的或者异源的。在另一个实施方案中，第一重链和第二重链中包含的可变区与Fc区直接连接或者通过接头连接。在一个具体实施方案中，所述接头是本领域通用的柔性接头。在另一个实施方案中，所述接头是(G4S)n，其中n＝1-6，优选n＝1,2,3或4。
在另一方面，本发明提供了抗CD79b×CD3双特异性抗体，其包含第一轻链、第一重链、第二重链和第二轻链，其中：
1)第一轻链包含与SEQ ID NO:10具有至少90％、91％、92％、93％、94％、95％、96％、97％、 98％、99％或更多序列同一性的序列，或者由SEQ ID NO:10组成；第一重链包含与SEQ ID NO:5具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:5组成；第二重链包含与SEQ ID NO:35具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:35组成；第二轻链包含与SEQ ID NO:40具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:40组成；
2)第一轻链包含与SEQ ID NO:10具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:10组成；第一重链包含与SEQ ID NO:5具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:5组成；第二重链包含与SEQ ID NO:45具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:45组成；第二轻链包含与SEQ ID NO:50具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:50组成；
3)第一轻链包含与SEQ ID NO:20具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:20组成；第一重链包含与SEQ ID NO:15具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:15组成；第二重链包含与SEQ ID NO:35具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:35组成；第二轻链包含与SEQ ID NO:40具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:40组成；
4)第一轻链包含与SEQ ID NO:20具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:20组成；第一重链包含与SEQ ID NO:15具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:15组成；第二重链包含与SEQ ID NO:45具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:45组成；第二轻链包含与SEQ ID NO:50具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:50组成；
5)第一轻链包含与SEQ ID NO:30具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:30组成；第一重链包含与SEQ ID NO:25具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:25组成；第二重链包含与SEQ ID NO:35具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:35组成；第二轻链包含与SEQ ID NO:40具有至少90％、91％、92％、93％、94％、95％、96％、 97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:40组成；
或
6)第一轻链包含与SEQ ID NO:30具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:30组成；第一重链包含与SEQ ID NO:25具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:25组成；第二重链包含与SEQ ID NO:45具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:45组成；第二轻链包含与SEQ ID NO:50具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多序列同一性的序列，或者由SEQ ID NO:50组成。
在一个实施方案中，第一轻链的轻链可变结枃域和第一重链的重链可变结构域配对形成CD79b的抗原识别位点，第二重链的重链可变结枃域和第二轻链的轻链可变结构域配对形成CD3的抗原识别位点。第一重链和第二重链各自的Fc结构域相互作用，形成Fc区。在一个具体的实施方案中，第一重链和第二重链各自的Fc结构域中含有稳定相互作用的突变，例如含有“杵入臼”突变。
在一个方面，本发明还提供了编码本发明抗CD79b×CD3双特异性抗体的多核苷酸(核酸)、包含所述多核苷酸的载体，优选地表达载体。
在另一个方面，本发明提供了包含本发明多核苷酸或载体的宿主细胞。本发明也提供了一种用于产生本发明抗CD79b×CD3双特异性抗体的方法，包括步骤(i)在适于表达本发明抗CD79b×CD3双特异性抗体的条件下培养本发明的宿主细胞，和(ii)回收本发明的抗CD79b×CD3双特异性抗体。
在一个方面，本发明提供了一种包含本发明抗CD79b×CD3双特异性抗体的诊断试剂盒和药物组合物。进一步地，还提供了本发明的抗CD79b×CD3双特异性抗体、诊断试剂盒或药物组合物的用途，用于治疗、预防和/或诊断与CD79b活性相关的疾病，特别地用于治疗、预防和/或诊断非霍奇金淋巴瘤。
在另一个方法，本发明提供了治疗与CD79b活性相关的疾病的方法，包括将治疗有效量的本发明的抗CD79b×CD3双特异性抗体，或本发明的药物组合物施用给有需要的患者。优选地，所述疾病是过量表达CD79b的癌症，更优选所述疾病是非霍奇金淋巴瘤。
除非另外限定，否则本文中所用的全部技术与科学术语具有如本发明所属领域的普通技术人员通常理解的相同含义。本文所提及的全部出版物、专利申请、专利和其他参考文献通过引用的方式完整地并入。此外，本文中所述的材料、方法和例子仅是说明性的并且不意在是限制性的。本发明的其他特征、目的和优点将从本说明书及附图并且从后附的权利要求书中显而易见。
附图说明
结合以下附图一起阅读时，将更好地理解以下详细描述的本发明的优选实施方案。出于说明本发明的目的，图中显示了目前优选的实施方案。然而，应当理解本发明不限于图中所示实施方案的精确安排和手段。
图1.嵌合抗CD79b抗体与Ramos细胞的结合能力
图2.嵌合抗CD79b抗体与BJAB细胞的结合能力
图3.人源化抗CD79b抗体与Ramos细胞的结合能力
图4.人源化抗CD79b抗体与BJAB细胞的结合能力
图5.人源化抗CD79b抗体ADCC活性检测
图6.示例抗体与BJAB细胞的结合能力。
图7.示例抗体与WSU-DLCL2细胞的结合能力。
图8.示例抗体介导的NFAT信号的激活作用。
图9.示例抗体介导的人CD8+T细胞对肿瘤细胞的杀伤作用。
图10.流式细胞技术检测示例抗体对人CD8+T细胞激活作用。
图11.流式细胞技术检测示例抗体诱导的人CD8+T细胞对肿瘤细胞的杀伤过程伴随的细胞因子IFN-γ的释放量。
图12.流式细胞技术检测示例抗体诱导的人CD8+T细胞对肿瘤细胞的杀伤过程伴随的细胞因子TNFα的释放量。
图13.流式细胞技术检测示例抗体对人CD4+T细胞激活作用。
图14.示例抗体促进CD8+T细胞增殖。
图15.示例抗体促进人CD4+T细胞增殖。
图16.示例抗体在WSU-DLCL2荷瘤人源化小鼠模型中的抑瘤作用。
图17.示例抗体在Ramos荷瘤人源化小鼠模型中的抑瘤作用。
图18.双特异性抗体在小鼠中的PK。
具体实施方式
I.定义
在下文详细描述本发明前，应理解本发明不限于本文中描述的特定方法学、方案和试剂，因为这些可以变化。还应理解本文中使用的术语仅为了描述具体实施方案，而并不意图限制本发明的范围，其仅会由所附权利要求书限制。除非另外定义，本文中使用的所有技术和科学术语与本发明所属领域中普通技术人员通常的理解具有相同的含义。
为了解释本说明书，将使用以下定义，并且只要适当，以单数形式使用的术语也可以包括复数，并且反之亦然。要理解，本文所用的术语仅是为了描述具体的实施方案，并且不意欲是限制性的。
术语“约”在与数字数值联合使用时意为涵盖具有比指定数字数值小5％的下限和比指定数字数值大5％的上限的范围内的数字数值。
术语“和/或”意指当用于连接两个或多个可选项时，应理解为意指可选项中的任一项或可选项中的任意两项或更多项。
术语“包含”或“包括”意指包括所述的要素、整数或步骤，但是不排除任意其它要素、整数或步骤。在 本文中，当使用术语“包含”或“包括”时，除非另有指明，否则也涵盖由所述及的要素、整数或步骤组合的情形。例如，当提及“包含”某个具体序列的抗体可变区时，也旨在涵盖由该具体序列组成的抗体可变区。
术语“抗体”在本文中以最广意义使用并且涵盖多种抗体结构物，包括但不限于单克隆抗体、多克隆抗体、重组抗体、人源化抗体、嵌合抗体、多特异性抗体(例如，双特异性抗体)、单链抗体、完整抗体或其显示出所需的抗原结合活性的抗体片段。完整抗体通常将包含至少两条全长重链和两条全长轻链，但在某些情况下可包括较少的链，例如骆驼中天然存在的抗体可仅包含重链。
术语“抗原结合片段”(在本文中可与“抗体片段”和“抗原结合部分”互换使用)，指与完整抗体不同的分子，其包含完整抗体的一部分且结合完整抗体所结合的抗原。抗原结合片段的例子包括但不限于Fv，Fab，Fab’，Fab’-SH，F(ab’) 2；双抗体(diabodies,dAb)；线性抗体；单链抗体(例如scFv)；单结构域抗体(单域抗体)；双价或双特异性抗体的抗原结合片段；骆驼科抗体；和表现出所需的结合抗原(例如CD79b和/或CD3)能力的其它片段。
如本文所用，术语“结合”和“特异性结合”意指抗体的结合作用对抗原是选择性的，并且可以与不想要的或非特异的相互作用区别开。抗体与特定抗原结合的能力可以通过酶联免疫吸附测定法(ELISA)、表面等离子共振法(SPR)或生物膜层光学干涉技术(ForteBio)或本领域已知的其它常规结合测定法测定。例如在SPR中，抗体以大约1×10 -7或更低的KD，大约1×10 -8或更低的KD，大约1×10 -9或更低的KD，大约1×10 -10或更低的KD、大约1×10 -11或更低的KD与CD79b或CD3结合，则该抗体是“与CD79b或CD3特异性结合”的抗体。然而，特异性结合CD79b或CD3的抗体可以与来自其它物种的CD79b或CD3蛋白具有交叉反应性。例如，特异于人CD79b或CD3的抗体，在一些实施方案中，可以与食蟹猴CD79b或CD3发生交叉反应。测定交叉反应性的方法包括实施例中所述的方法以及本领域已知的标准测定法，例如通过使用生物光干涉，或流式细胞术技术。
术语“单链可变片段”或“scFv”是一种小分子的基因工程抗体，它是在DNA水平上利用基因工程方法将天然抗体的重链可变区(VH)和轻链可变区(VL)连接(通常通过一段人工合成的连接肽(或“接头”)连接)而成的小分子重组抗体。与完整抗体分子相比，scFv单链抗体具有以下优点：含有完整的抗体可变区，保留原抗体的抗原特异性和结合活性；不含有抗体分子的Fc区，因而免疫原性弱，用于人体不易产生免疫反应；易于操作，适用于作为基因工程构件，制备具有新性质的其它抗原特异性结合分子，例如全长抗体、scFv-Fc等。
术语“Fc区”在本文中用于定义免疫球蛋白重链的C端区域，所述区域包含至少一部分的恒定区。该术语包括天然序列Fc区和变体Fc区。在某些实施方案中，人IgG重链Fc区通常从Cys226或Pro230延伸至重链的羰基端。然而，Fc区的C端赖氨酸(Lys447)可以存在或者可以不存在。除非另外说明，Fc区或恒定区中的氨基酸残基的编号是根据EU编号系统，其也被称为EU索引，如在Kabat等，Sequences of Proteins of Immunological Interest，5 th Ed.Public Health Service，National Institutes of Health，Bethesda，MD，1991中所述。
术语“杵入臼”指在本申请所述的双特异性抗体分子的一条Fc链上产生“杵”结构，而在另一条链上产生 “臼”结构，从而使得该臼与该杵具有相同或相似的大小，适宜地放置，使得在两个Fc相互作用时，一个Fc的杵可定位在另一个Fc对应的臼中，从而稳定了异源多聚体的结构(参见例如美国专利号5,731,168)。
在一些实施方案中，根据本领域现有技术，杵可以通过用较大的侧链取代小的氨基酸侧链来构建。在一些实施方案中，臼可以通过用较小的侧链取代大的氨基酸侧链来构建。
术语“可变区”或“可变结构域”是指参与抗体与抗原结合的抗体重或轻链的结构域。天然抗体的重链和轻链的可变结构域通常具有相似的结构，其中每个结构域包含四个保守的框架区(FR)和三个互补决定区(参见，例如，Kindt等Kuby Immunology，6 th ed.，W.H.Freeman and Co.91页(2007))。单个VH或VL结构域可以足以给予抗原结合特异性。
“互补决定区”或“CDR区”或“CDR”或“高变区”，是抗体可变结构域中在序列上高度可变并且形成在结构上确定的环(“超变环”)和/或含有抗原接触残基(“抗原接触点”)的区域。CDR主要负责与抗原表位结合。重链和轻链的CDR从N-端开始顺序编号，通常称作CDR1、CDR2和CDR3。位于抗体重链可变结构域内的CDR也称作HCDR1、HCDR2和HCDR3，而位于抗体轻链可变结构域内的CDR则称作LCDR1、LCDR2和LCDR3。在一个给定的轻链可变区或重链可变区氨基酸序列中，可以采用本领域公知的多种方案确定其CDR序列，例如：基于抗体的三维结构和CDR环的拓扑学的Chothia(Chothia等人.(1989)Nature 342:877-883，Al-Lazikani等人,“Standard conformations for the canonical structures of immunoglobulins”,Journal of Molecular Biology,273,927-948(1997))，基于抗体序列可变性的Kabat(Kabat等人,Sequences of Proteins of Immunological Interest,第4版,U.S.Department of Health and Human Services,National Institutes of Health(1987)),AbM(University of Bath)，Contact(University College London)，国际ImMunoGeneTics database(IMGT)(国际免疫遗传学信息系统,万维网imgt.cines.fr/)，以及基于利用大量晶体结构的近邻传播聚类(affinity propagation clustering)的North CDR定义(North等，“A New Clustering of Antibody CDR Loop Con格式ions”，Journal of Molecular Biology，406，228-256(2011))。
例如，使用Kabat和Chothia编号的CDR区域的不同定义范围。
Figure PCTCN2022108881-appb-000001
Figure PCTCN2022108881-appb-000002
除非另有说明，否则在本发明中，术语“CDR”或“CDR序列”涵盖以上述任一种方式确定的CDR序列。
CDR也可以基于与参考CDR序列具有相同的Kabat编号位置而确定。除非另有说明，否则在本发明中，当提及抗体可变区中的残基位置(包括重链可变区残基和轻链可变区残基)时，是指根据Kabat编号系统(Kabat等人，Sequences of Proteins of Immunological Interest,5 th Ed.Public Health Service,National Institutes of Health,Bethesda,Md.(1991))的编号位置。
然而，应该注意，基于不同的指派系统获得的同一抗体的可变区的CDR的边界可能有所差异。即不同指派系统下定义的同一抗体可变区的CDR序列有所不同。因此，在涉及用本发明定义的具体CDR序列限定抗体时，所述抗体的范围还涵盖了这样的抗体，其可变区序列包含所述的具体CDR序列，但是由于应用了不同的方案(例如不同的指派系统规则或组合)而导致其所声称的CDR边界与本发明所定义的具体CDR边界不同。
具有不同特异性(即，针对不同抗原的不同结合位点)的抗体具有不同的CDR。然而，尽管CDR在抗体与抗体之间是不同的，但是CDR内只有有限数量的氨基酸位置直接参与抗原结合。使用Kabat,Chothia,AbM、Contact和North方法中的至少两种，可以确定最小重叠区域，从而提供用于抗原结合的“最小结合单位”。最小结合单位可以是CDR的一个子部分。正如本领域技术人员明了，通过抗体的结构和蛋白折叠，可以确定CDR序列其余部分的残基。因此，本发明也考虑本文所给出的任何CDR的变体。例如，在一个CDR的变体中，最小结合单位的氨基酸残基可以保持不变，而根据Kabat或Chothia定义的其余CDR残基可以被保守氨基酸残基替代。
术语“细胞毒性剂”用在本发明中指抑制或防止细胞功能和/或引起细胞死亡或破坏的物质。
术语“化疗剂”包括在治疗癌症中有用的化学化合物。
术语“小分子药物”是指低分子量的能够调节生物过程的有机化合物。“小分子”被定义为分子量小于10kD、通常小于2kD和优选小于1kD的分子。小分子包括但不限于无机分子、有机分子、含无机组分的有机分子、含放射性原子的分子、合成分子、肽模拟物和抗体模拟物。作为治疗剂，小分子可以比大分子更能透过细胞、对降解更不易感和更不易于引发免疫应答。
术语“功能性Fc区”指这样的Fc区，其拥有天然序列Fc区的“效应器功能”。例示性的“效应器功能”包括C1q结合；CDC；Fc受体结合；ADCC；吞噬作用；细胞表面受体(例如B细胞受体；BCR)下调等。此类效应器功能一般要求Fc区与结合结构域(例如抗体可变域)联合，而且可以使用多种测定法来评估，例如本文所公开的那些。
本文所述的术语“治疗剂”涵盖在预防或治疗肿瘤(例如癌症)中有效的任何物质，包括化疗剂、细胞毒性剂、疫苗、其它抗体、抗感染活性剂、小分子药物或免疫调节剂。
本文使用的术语“免疫调节剂”指抑制或调节免疫应答的天然或合成活性剂或者药物。免疫应答可以是体液应答或细胞应答。
术语“有效量”指本发明的抗体或其片段或缀合物或组合物这样的量或剂量，其以单一或多次剂量施用患者后，在需要治疗或预防的患者中产生预期效果。针对治疗或预防的目的，可以将“有效量”区分为“治疗有效量”和“预防有效量”。有效量可以由作为本领域技术人员的主治医师通过考虑以下多种因素而容易地确定：诸如哺乳动物的物种、大小、年龄和一般健康、涉及的具体疾病、疾病的程度或严重性、个体患者的应答、施用的具体抗体、施用模式、施用制剂的生物利用率特征、选择的给药方案、和任何伴随疗法的使用。
在一个实施方式中，相比较于对照，有效量的本发明双特异性抗体优选地抑制可度量参数(例如肿瘤生长率，肿瘤体积等)至少约20％、更优选地至少约40％、甚至更优选地至少约50％、60％或70％和仍更优选地至少约80％或90％。
术语“宿主细胞”、“宿主细胞系”和“宿主细胞培养物”可交换地使用且是指其中引入外源核酸的细胞，包括这种细胞的后代。宿主细胞包括“转化体”和“转化的细胞”，其包括最初原代转化的细胞和来源于其的后代，而不考虑传代的数目。后代在核酸内容上可能与亲本细胞不完全相同，而是可以包含突变。本文中包括在最初转化的细胞中筛选或选择的具有相同功能或生物学活性的突变体后代。
如本文所用，术语“多特异性”抗体指具有至少两个不同抗原结合位点的抗体，所述至少两个不同抗原结合位点中的每一个抗原结合位点与相同抗原的不同表位或与不同抗原的不同表位结合。多特异性抗体是对至少两个不同抗原表位具有结合特异性的抗体。在一个实施方案中，本文提供了这样的双特异性抗体，其具有针对第一抗原或靶标(CD79b)和第二抗原靶标(CD3)的结合特异性。鉴于根据本发明的抗体构建体是(至少)双特异性的，其不是天然存在的并且其与天然存在的产物明显不同。因此，“双特异性”抗体或免疫球蛋白是具有至少两个具有不同特异性的不同结合侧的人工杂交抗体或免疫球蛋白。
术语“靶标”表示CD79b或CD3。术语“第一靶标和第二靶标”表示CD79b作为第一个靶标和CD3作为第二个靶标或反之亦然。
术语“细胞因子”是由一种细胞群释放，作为细胞间介质作用于另一细胞的蛋白质的通称。此类细胞因子的例子有淋巴因子、单核因子、白介素(IL)，诸如IL-1，IL-1α，IL-2，IL-3，IL-4，IL-5，IL-6，IL-7，IL-8，IL-9，IL-11，IL-12，IL-15；肿瘤坏死因子，诸如TNF-α或TNF-β；及其它多肽因子，包括LIF和kit配体(KL)和γ-干扰素。如本文中使用的，术语细胞因子包括来自天然来源或来自重组细胞培养物的蛋白质及天然序列细胞因子的生物学活性等效物，包括通过人工合成产生的小分子实体，及其药剂学可接受的衍生物和盐。
术语“免疫缀合物”是与一个或多个其它物质(包括但不限于细胞毒性剂或标记)缀合的抗体。
术语“个体”或“受试者”包括哺乳动物。哺乳动物包括但不限于，家养动物(例如，牛，羊，猫，狗和马)， 灵长类动物(例如，人和非人灵长类动物如猴)，兔，以及啮齿类动物(例如，小鼠和大鼠)。在一些实施方案中，个体或受试者是人。
术语“分离的”抗体是这样的抗体，其已经与其天然环境的组分分离。在一些实施方案中，将抗体纯化至超过95％或99％纯度，如通过例如电泳(例如，SDS-PAGE，等电聚焦(IEF)，毛细管电泳)或层析(例如，离子交换或反相HPLC)确定的。对于用于评估抗体纯度的方法的综述，参见，例如，Flatman等，J.Chromatogr.B848：79-87(2007)。
如下进行序列之间序列同一性的计算。
为确定两个氨基酸序列或两个核酸序列的同一性百分数，将所述序列出于最佳比较目的比对(例如，可以为了最佳比对而在第一和第二氨基酸序列或核酸序列之一或二者中引入空位或可以为比较目的而抛弃非同源序列)。在一个优选实施方案中，为比较目的，所比对的参考序列的长度是至少30％、优选地至少40％、更优选地至少50％、60％和甚至更优选地至少70％、80％、90％、100％的参考序列长度。随后比较在对应氨基酸位置或核苷酸位置处的氨基酸残基或核苷酸。当第一序列中的位置由第二序列中对应位置处的相同氨基酸残基或核苷酸占据时，则所述分子在这个位置处是相同的。
可以利用数学算法实现两个序列间的序列比较和同一性百分数的计算。在一个优选实施方案中，使用已经集成至GCG软件包的GAP程序中的Needlema和Wunsch((1970)J.Mol.Biol.48:444-453)算法(在http://www.gcg.com可获得)，使用Blossum 62矩阵或PAM250矩阵和空位权重16、14、12、10、8、6或4和长度权重1、2、3、4、5或6，确定两个氨基酸序列之间的同一性百分数。在又一个优选的实施方案中，使用GCG软件包中的GAP程序(在http://www.gcg.com可获得)，使用NWSgapdna.CMP矩阵和空位权重40、50、60、70或80和长度权重1、2、3、4、5或6，确定两个核苷酸序列之间的同一性百分数。特别优选的参数集合(和除非另外说明否则应当使用的一个参数集合)是采用空位罚分12、空位延伸罚分4和移码空位罚分5的Blossum 62评分矩阵。
还可以使用PAM120加权余数表、空位长度罚分12，空位罚分4)，利用已经并入ALIGN程序(2.0版)的E.Meyers和W.Miller算法,((1989)CABIOS,4:11-17)确定两个氨基酸序列或核苷酸序列之间的同一性百分数。
额外地或备选地，可以进一步使用本文所述的核酸序列和蛋白质序列作为“查询序列”以针对公共数据库执行检索，以例如鉴定其它家族成员序列或相关序列。
术语“药用辅料”指与活性物质一起施用的稀释剂、佐剂(例如弗氏佐剂(完全和不完全的))、赋形剂、载体或稳定剂等。
术语“药物组合物”指这样的组合物，其以允许包含在其中的活性成分的生物学活性有效的形式存在，并且不包含对施用所述组合物的受试者具有不可接受的毒性的另外的成分。
术语“组合疗法”或“联合疗法”是指施用两种或更多种治疗剂以治疗如本公开所述的癌症或感染。这种施用包括以基本上同时的方式共同施用这些治疗剂，例如以具有固定比例的活性成分的单一胶囊。或者，这种施用包括对于各个活性成分在多种或在分开的容器(例如片剂、胶囊、粉末和液体)中的共同施用。粉 末和/或液体可以在施用前重构或稀释至所需剂量。此外，这种施用还包括以大致相同的时间或在不同的时间以顺序的方式使用每种类型的治疗剂。在任一情况下，治疗方案将提供药物组合在治疗本文所述的病症或病状中的有益作用。
用于本文时，“治疗”指减缓、中断、阻滞、缓解、停止、降低、或逆转已存在的症状、病症、病况或疾病的进展或严重性。
用于本文时，“预防”包括对疾病或病症或特定疾病或病症的症状的发生或发展的抑制。在一些实施方式中，具有癌症家族病史的受试者是预防性方案的候选。通常，在癌症的背景中，术语“预防”是指在癌症的病征或症状发生前，特别是在具有癌症风险的受试者中发生前的药物施用。
术语“载体”当在本文中使用时是指能够增殖与其相连的另一个核酸的核酸分子。该术语包括作为自我复制核酸结构的载体以及结合到已经引入其的宿主细胞的基因组中的载体。一些载体能够指导与其可操作相连的核酸的表达。这样的载体在本文中被称为“表达载体”。
II.抗体
如本文所用的术语“CD79b、靶CD79b、人CD79b”指CD79b重组蛋白，。CD79b的胞外结构域根据UniProt由氨基酸29-159组成。本文所述及的“针对CD79b的抗体”、“抗CD79b抗体”指特异性结合CD79b的抗体。。在一个实施方案中，结合至CD79b的抗体具有10 -9M或更低、优选10 -9M至10 -13M的解离常数(Kd)。在一个实施方案中，所述抗CD79b抗体结合至CD79b的表位，所述表位在来自不同物种的CD79b中、优选在人中是保守的。
在一个实施方案中，本文述及的“抗CD79b抗体”包含重链可变区和轻链可变区，重链可变区包含来自SEQ ID NO:4，14或24的CDR，轻链可变区包含来自SEQ ID NO:9，19或29的CDR。
T细胞或T淋巴细胞是在细胞介导的免疫中发挥核心作用的一类淋巴细胞。T细胞应答的特异性由TCR对抗原(在主要组织相容性复合体MHC的环境中展示)的识别来介导。作为TCR的一部分，CD3受体复合物是一种蛋白质复合物，包含CD3γ(gamma)链、CD3δ(delta)链和存在于细胞表面的两条CD3ε(epsilon)链，参与激活细胞毒性T细胞(CD8+幼稚T细胞)和T辅助细胞(CD4+幼稚T细胞)。CD3在T细胞上诸如通过固定化抗CD3抗体的簇集，导致T细胞活化，这类似于T细胞受体的接合，但不依赖于其克隆特有的特异性。
发现CD3与所有成熟T细胞的膜结合，这种高特异性，再加上在T细胞发育各个阶段都存在CD3，使其成为组织切片中T细胞有用的免疫组织化学标记。设想根据本发明的抗体构建体通常并且有利地显示更少的非特异性T细胞活化，其在特异性免疫疗法中是不需要的。这意味着副作用的风险降低。
本文所述及的“抗CD3抗体”指结合CD3的抗体。在一个实施方案中，本文述及“抗CD3抗体"包含重链可变区和轻链可变区，重链可变区包含来自SEQ ID NO:34或44的CDR，轻链可变区包含来自SEQ ID NO:39或49的CDR。
本文述及的“抗CD79b和CD3的双特异性抗体”、“特异性结合CD79b和CD3的双特异性抗体”、“抗CD79b×CD3双特异性抗体”、“CD79b/CD3双抗”等术语指能够以足够亲和力结合靶标CD79b和CD3的双特异性抗体，所述双特异性抗体能够募集T细胞，对靶细胞进行重定向溶解。接合的T细胞能够连续靶细胞溶 解，并且不受干扰肽抗原加工和呈递或克隆T细胞分化免疫逃逸机制的影响。在一个实施方案中，本文述及的“抗CD79b和CD3的双特异性抗体”包含靶向CD79b的重链可变区和轻链可变区，重链可变区包含来自SEQ ID NO:4，14或24的CDR，轻链可变区包含来自SEQ ID NO:9，19或29的CDR，以及靶向CD3的重链可变区和轻链可变区，重链可变区包含来自SEQ ID NO:34或44的CDR，轻链可变区包含来自SEQ ID NO:39或49的CDR。所述抗体可以用作靶向表达CD79b的癌症的诊断剂和/或治疗剂。
本发明提供的抗CD79b×CD3双特异性抗体具有如下优点：
在一些实施方案中，本发明的抗CD79b×CD3双特异性抗体，通过将不同的抗CD79b抗体与具有不同亲和力的抗CD3抗体组装形成，通过在抗CD79b×CD3双特异性抗体诱导的CD8+T对肿瘤细胞的杀伤实验中引入对T细胞激活程度和多种细胞因子释放水平的检测，有利于早期(体外筛选阶段)对CD79b/CD3双抗的药效和安全性进行综合性评估。筛选体外筛选阶段的最大杀伤类似而细胞因子释放水平较低的差异化的分子进行体内实验和毒理实验，有助于降低此类双抗临床应用过程中细胞因子风暴的风险。
在一些实施方案中，本发明的CD79b/CD3双抗同时结合B细胞非霍奇金淋巴瘤细胞表面的CD79b和原代T细胞表面的CD3，介导T细胞对CD79b阳性肿瘤细胞的杀伤。在一些实施方案中，本发明的双特异性抗体能够剂量依赖性地诱导CD8+T对具有不同CD79b表达水平的B细胞非霍奇金淋巴瘤细胞的杀伤作用。
在一些实施方案中，本发明的抗CD79b×CD3抗体介导人B细胞非霍奇金淋巴瘤细胞的杀伤，并剂量依赖性地激活从PBMC分离的CD8+T细胞和CD4+T细胞。在一些实施方案中，本发明的抗体促进人CD8+T、CD4+T细胞的增殖能力。
在一些实施方案中，本发明的抗体能有效地抑制肿瘤的生长，相比较于对照，肿瘤抑制率可以达到67％，甚至100％。
在本发明的一个实施方案中，本文涵盖具有氨基酸改变的抗CD79b×CD3双特异性抗体，其中所述的氨基酸改变包括氨基酸的置换、插入或缺失。优选的，本文所述的氨基酸改变为氨基酸置换，优选地保守置换。
在优选的实施方案中，本发明所述的氨基酸改变发生在CDR外的区域(例如在FR中)。更优选地，本发明所述的氨基酸改变发生在重链可变区外和/或轻链可变区外的区域。
在一些实施方案中，置换为保守性置换。保守置换是指一个氨基酸经相同类别内的另一氨基酸置换，例如一个酸性氨基酸经另一酸性氨基酸置换，一个碱性氨基酸经另一碱性氨基酸置换，或一个中性氨基酸经另一中性氨基酸置换。示例性的置换如下表所示：
原始残基 示例性置换 优选的保守氨基酸置换
Ala(A) Val、Leu、Ile Val
Arg(R) Lys、Gln、Asn Lys
Asn(N) Gln、His、Asp、Lys、Arg Gln
Asp(D) Glu、Asn Glu
Cys(C) Ser、Ala Ser
Gln(Q) Asn、Glu Asn
Glu(E) Asp、Gln Asp
Gly(G) Ala Ala
His(H) Asn、Gln、Lys、Arg Arg
Ile(I) Leu、Val、Met、Ala、Phe、正亮氨酸 Leu
Leu(L) 正亮氨酸、Ile、Val、Met、Ala、Phe Ile
Lys(K) Arg、Gln、Asn Arg
Met(M) Leu、Phe、Ile Leu
Phe(F) Trp、Leu、Val、Ile、Ala、Tyr Tyr
Pro(P) Ala Ala
Ser(S) Thr Thr
Thr(T) Val、Ser Ser
Trp(W) Tyr、Phe Tyr
Tyr(Y) Trp、Phe、Thr、Ser Phe
Val(V) Ile、Leu、Met、Phe、Ala、正亮氨酸 Leu
在某些实施方案中，置换发生在抗体的CDR区。通常，获得的变体相对于亲本抗体在某些生物学特性方面(例如，增加的亲和力)具有修饰(例如，改善)和/或将具有亲本抗体的基本上保留的某些生物学特性。示例性置换变体是亲和力成熟抗体。
在某些实施方案中，本文中所提供的抗体经改变以增加或降低抗体经糖基化的程度。对抗体的糖基化位点的添加或缺失可通过改变氨基酸序列以便产生或移除一或多个糖基化位点而方便地实现。当抗体包含Fc区时，可以改变附着于其的糖类。在一些应用中，除去不想要的糖基化位点的修饰可以是有用的，例如除去岩藻糖模块以提高抗体依赖性细胞介导的细胞毒性细胞毒性(ADCC)功能(参见Shield等(2002)JBC277:26733)。在其它应用中，可以进行半乳糖苷化修饰以修饰补体依赖性细胞毒性(CDC)。
在某些实施方案中，可在本文中所提供抗体的Fc区中引入一个或多个氨基酸修饰，以此产生Fc区变体。Fc区变体可包括在一或多个氨基酸位置处包含氨基酸修饰(例如置换)的人Fc区序列(例如人IgGl、IgG2、IgG3或IgG4Fc区)。关于Fc变体的实例参见美国专利号7,332,581，美国专利号6,737,056，美国专利号6,737,056；WO 2004/056312和Shields等人，J.Biol.Chem.9(2):6591-6604(2001)，美国专利号6,194,551、WO99/51642和Idusogie等人J.Immunol.164:4178-4184(2000)，美国专利号7,371,826，Duncan&Winter,Nature 322:738-40(1988)；美国专利号5,648,260；美国专利号5,624,821；和WO 94/29351。
在某些实施方案中，可能需要产生经半胱氨酸工程改造的抗体，例如“硫代MAb”，其中抗体的一或多个残基经半胱氨酸残基置换。可以如，例如美国专利号7,521,541中所述地生成半胱氨酸改造的抗体。
在某些实施方案中，本文中所提供的抗体可进一步经修饰为含有本领域中已知且轻易获得的其它非蛋白质部分。适合抗体衍生作用的部分包括，但不限于，水溶性聚合物。水溶性聚合物的非限制性实例包括，但不限于，聚乙二醇(PEG)、乙二醇/丙二醇共聚物、羧甲基纤维素、葡聚糖、聚乙烯醇、聚乙烯吡咯烷酮、聚-1,3-二烷、聚-1,3,6-三烷、乙烯/马来酸酐共聚物、聚氨基酸(均聚物或无规共聚物)、及葡聚糖或聚(n-乙烯基吡咯烷酮)聚乙二醇、丙二醇均聚物、聚环氧丙烷/氧化乙烯共聚物、聚氧乙基化多元醇(例如甘油)、聚乙烯醇、及其混合物。
III.本发明的核酸以及包含其的载体和宿主细胞
在一方面，本发明提供了编码以上任何抗CD79b、抗CD3和抗CD79b×CD3抗体或其抗原结合片段的核酸。本发明还涵盖与上述核酸在严格性条件下杂交的核酸，与上述核酸相比具有一个或多个置换(例如保守性置换)、缺失或插入的核酸，或与上述核酸相比具有至少80％，至少85％，至少90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或更多同一性的核酸序列。
在另一方面，本发明提供了包含上述核酸的载体。在一个优选的实施方案中，所述载体是表达载体。本领域技术人员完全可以理解，在本发明所属的技术领域中通常采用的载体可以应用于本发明。
在一个实施方案中，本发明提供了包含所述核酸或所述载体的宿主细胞。用于克隆或表达编码抗体的载体的适当宿主细胞包括本文描述的原核或真核细胞。在一个实施方案中，宿主细胞是真核的。在另一个实施方案中，宿主细胞选自酵母细胞、哺乳动物细胞(例如CHO细胞或293细胞)或适用于制备抗体或其抗原结合片段的其它细胞。
IV.药物组合物
在一些实施方案中，本发明提供包含本文所述的任何抗CD79b×CD3抗体或其抗原结合片段的组合物，优选地组合物为药物组合物。在一个实施方案中，所述组合物还包含药用辅料。在一个实施方案中，组合物(例如，药物组合物)包含本发明的抗CD79b×CD3抗体或其抗原结合片段，以及一种或多种其它治疗剂(例如化疗剂、细胞毒性剂、疫苗、其它抗体、抗感染活性剂、小分子药物或免疫调节剂)的组合。
本发明的药物组合物还可以包含一种或多种其它活性成分，所述活性成分是被治疗的特定适应证所需的，优选具有不会不利地影响彼此活性的那些活性成分。例如，理想的是还提供其它抗癌活性成分，例如化疗剂、细胞毒性剂、疫苗、其它抗体、抗感染活性剂、小分子药物或免疫调节剂等。所述活性成分以对于目的应用有效的量合适地组合存在。
实施例
描述以下实施例以辅助对本发明的理解。不意在且不应当以任何方式将实施例解释成限制本发明的保护范围，根据本申请说明书的描述，本领域技术人员可以进行多种修改。
除非明确指明相反，否则本发明的实施将采用本领域技术内的常规化学、生物化学、有机化学、分子生物学、微生物学、重组DNA技术、遗传学、免疫学和细胞生物学的方法。这些方法的描述可以参见， 例如，Sambrook等人，Molecular Cloning:A Laboratory Manual(第3版，2001)；Sambrook等人，Molecular Cloning:A Laboratory Manual(第2版,1989)；Maniatis等人，Molecular Cloning:A Laboratory Manual(1982)；Ausubel等人，Current Protocols in Molecular Biology(John Wiley和Sons,2008年7月更新)；Short Protocols in Molecular Biology:A Compendium of Methods from Current Protocols in Molecular Biology,Greene Pub.Associates和Wiley-Interscience；Glover,DNA Cloning:A Practical Approach,vol.I&II(IRL Press,Oxford,1985)；Anand,Techniques for the Analysis of Complex Genomes,(Academic Press,New York,1992)；Transcription and Translation(B.Hames&S.Higgins,Eds.,1984)；Perbal,A Practical Guide to Molecular Cloning(1984)；Harlow和Lane,Antibodies,(Cold Spring Harbor Laboratory Press,Cold Spring Harbor,N.Y.,1998)Current Protocols in Immunology Q.E.Coligan,A.M.Kruisbeek,D.H.Margulies,E.M.Shevach和W.Strober,eds.,1991)；Annual Review of Immunology；以及期刊专著如Advances in Immunology。
本发明抗体的分子结构设计
本发明一方面设计靶向CD79b的单特异性抗体，可结合B细胞非霍奇金淋巴瘤细胞表面的CD79b，以5个抗CD79b抗体(34F1，11G10，38D9，54H6，60D9)为基础，经人源化分别得到人源化5个抗CD79b抗体(hz34F1.14，hz11G10.9.p1，hz38D9B3.11，hz54H6A3.13，hz60D9H6.2)
本发明另一方面设计同时靶向CD79b和CD3的T细胞整合器(T-cell engager)类双特异性抗体，可同时结合B细胞非霍奇金淋巴瘤细胞表面的CD79b和T细胞表面的CD3。以三个抗CD79b抗体(38D9B3.11,11G10.9.p1,34F1.14)和两个不同亲和力的抗CD3抗体(sp34.24,sp34.87)为基础，设计同时靶向CD79b和CD3的双特异性抗体。
设计1+1format的双特异性抗体分子共6个(38D9B3.11/sp34.87,38D9B3.11/sp34.24,11G10.9.p1/sp34.87,11G10.9.p1/sp34.24,34F1.14/sp34.87,34F1.14/sp34.24)。利用Fc“结入扣”(knob-in-hole)技术解决双特异性抗体的重链错配，Fc为IgG1的重链恒定区，同时引入减弱效应子功能(effector function)的L234A，L235A(根据Kabat的“EU”编号)氨基酸突变。
实施例1、杂交瘤细胞的制备
免疫
将CD79b蛋白(sino，Cat#29750-H08H)，与弗氏完全佐剂(sigma,Cat#F5881)乳化后免疫Balb/c小鼠(购自北京维通利华实验动物技术有限公司)，两周后再与弗氏不完全佐剂(sigma,Cat#F5506)乳化后免疫三次，每两周肌肉注射一次(每只小鼠50ug蛋白)。
细胞融合
当血清效价满足要求后，摘取小鼠的脾制备B淋巴细胞悬液，与SP2/0骨髓瘤细胞(ATCC)以1:2～1:1的比例混合后进行电融合。将融合后的细胞从电极皿中转移入50ml离心管中，用含HAT的培养基稀释细胞至1～2×10 4个细胞/ml，96孔板中每孔加入100μl细胞悬液。融合后第7天更换筛选培养基，培养第10天(或更久，根据细胞生长状态)后进行流式细胞术(FACS)检测，筛选阳性克隆。
杂交瘤细胞阳性克隆筛选(FACS)
通过流式细胞仪(FACS)筛选出特异性表达抗CD79b抗体的杂交瘤细胞。将待检测细胞(Ramos)计数，并稀释至1×10 6个细胞/ml，向U型底96孔板中加入100μl/孔。500g离心5min，去除细胞培养基。将杂交瘤96孔板培养上清加入U型板并重悬细胞，每孔加100μl，冰上静置30min。500g离心5min去除上清，PBS洗细胞1遍。500g 5min去除PBS，每孔加入100μl抗鼠Fab(Jackson Immunoresearch，Cat#115-545-006)的FITC标记的二抗(1:500稀释于PBS中)，阳性对照抗体加入100μl抗人Fc的PE(Biolegend，Cat#409304)标记的二抗。冰上避光孵育30min。500g 5min去除上清，PBS洗细胞1遍。用50μl 1×PBS重悬细胞，FACS上机检测。将阳性克隆进行亚克隆，挑取单克隆细胞。
阳性杂交瘤细胞亚克隆
亚克隆步骤：准备一块96孔板，每孔加入200μl培养基，该培养基是在筛选培养基的基础上将HAT更换成HT(Gibco,Cat#11067-030)，其余配方相同。将上述融合筛选出的阳性孔的细胞制成细胞悬液，分别取100ul加入到第一排的每个孔中混匀，然后将第1排细胞悬液取100μl加入第2排，充分混匀后取100μl加入下一排；重复上述步骤，静置96孔板30min，显微镜下观察计数。取100个细胞对应的体积加入20ml培养基，并混匀铺板，每孔200μl。一周后显微镜下观察，判断并标记出单克隆孔。待每孔细胞汇合度达到50％以上时，同上述FACS筛选方法检测，挑出目标阳性孔，并采用生物膜薄层干涉测定技术(ForteBio)测定所获得的杂交瘤细胞上清与抗原的亲和力。所有检测结果如表1所示：
表1.杂交瘤亚克隆上清检测结果
Figure PCTCN2022108881-appb-000003
实施例2、重组鼠源抗体的制备
对实施例1中获得的杂交瘤候选克隆进行抗体轻重链基因序列的调取。取新鲜培养的每株细胞约5×10 6个，抽提RNA(Macherey-Nagel，Cat#740984.250)。利用PrimeScript II 1st Strand cDNA Synthesis Kit(Takara)反转录获得cDNA。以位于5’端FR1区的碱基序列设计上游引物，以位于抗体恒定区或FR4区的碱基设计下游引物，扩增出抗体轻链和重链可变区基因片段。将其连接到T载体中(Mighty TA-cloning Kit试剂盒，Takara)，挑取单克隆进行测序，将测序结果利用MEGA7软件进行分析比对。最后，根据抗体轻重链可变区序列的特异性以及抗体的亲和力，将抗体进行重组鼠源抗体构建。
分别将其轻重链可变区基因片段通过南京诺维赞公司的同源重组酶(
Figure PCTCN2022108881-appb-000004
目录号：C112-01)连接到pcDNA3.1载体中，其中恒定区选择IgG1亚型，获得轻链和重链抗体的表达质粒。
然后将同一抗体的轻链质粒与重链质粒按1:1的摩尔比混合，经聚乙烯亚胺(PEI)(Polysciences，Cat#23966)转染293F细胞，培养5-7天后，细胞活力低于60％时，收集细胞培养上清并用Protein A亲和柱纯化出单克隆抗体。
实施例3、生物膜薄层干涉技术测定本发明的嵌合抗体与抗原的结合动力学
采用生物膜薄层干涉测定技术(ForteBio)测定本发明抗体结合CD79b的平衡解离常数(KD)。ForteBio亲和力测定按照现有的方法(Estep,P等人，High throughput solution Based measurement of antibody-antigen affinity and epitope binning.MAbs,2013.5(2):第270-8页)进行。
简言之，AMQ(Pall，1506091)传感器在分析缓冲液中线下平衡30分钟，然后线上检测60秒建立基线，在线加载如上所述获得的经纯化的抗体至AHQ传感器(ForteBio)上进行ForteBio亲和测量。再将具有加载的抗体的传感器暴露于抗原CD79b，之后将传感器转移至分析缓冲液用于解离速率测量。使用ForteBio分析软件分析KD值。抗体亲和力的检测结果如表2所示：
表2.ForteBio检测抗原抗体结合的亲和力(平衡解离常数KD)
Figure PCTCN2022108881-appb-000005
实施例4、嵌合抗体和B细胞非霍奇金淋巴瘤细胞系的结合实验
为了验证本发明的抗体是否可以和细胞表面表达的抗原相结合，本研究利用流式细胞技术检测了抗体和Ramos及BJAB细胞的结合，实验过程如下：
Ramos(ATCC，货号CRL-1596)和BJAB(美国AddexBio，货号C0003016)按照常规操作培养传代。细胞离心重悬后计数，将细胞密度调整至4X10 6cell/ml倒于加样槽中,用排枪以每孔50ul接种于96孔板中。每孔50ul细胞中加入50ul梯度稀释的抗体样品，然后放入37℃5％CO2的细胞培养箱中孵育30分钟。400g离心5分钟甩板，加入200ul PBS 400g 5分钟离心甩板,重复3次。加入山羊抗人IgG PE(1:200)室温避光孵育30分钟，200ul PBS洗2次甩板；重悬于100ul PBS，流式细胞仪读数。拟合曲线，计算EC50值。
在如以上测定法所述进行的实验中，嵌合抗体与Ramos细胞表面的CD79b结合见图1；嵌合抗体与BJAB细胞表面的CD79b结合见图2。
实施例5、嵌合抗体的人源化
根据常规方法，将实施例2得到的嵌合抗体进行人源化。由此获得人源化抗体：hz34F1.14,hz11G10.9.p1,hz38D9B3.11,hz54H6A3.13,hz60D6H6.2，其CDR序列、轻链可变区和重链可变区序列，轻链和重链的氨基酸序列参见实施例9。
实施例6、ForteBio测定人源化抗体与抗原的结合动力学
采用ForteBio测定法测定本发明的人源化抗体结合人CD79b的平衡解离常数(KD)。测定方法同实 施例3，数据见表3。
表3.ForteBio检测抗原抗体结合的亲和力常数(M)
Figure PCTCN2022108881-appb-000006
从表3人源化抗体与CD79b的亲和力可以看出，人源化后的抗体基本维持了之前嵌合抗体对于CD79b的结合。
实施例7、人源化抗体和B细胞非霍奇金淋巴瘤细胞系的结合实验
采用流式细胞技术检测人源化抗体和Ramos及BJAB细胞的结合。测定方法同实施例4，人源化抗体与Ramos细胞表面的CD79b结合见图3；人源化抗体与BJAB细胞表面的CD79b结合见图4。
实施例8、抗体介导ADCC效应的作用
本实施例研究了所获得抗体介导ADCC效应进而清除肿瘤细胞的作用。本研究使用Promega的Jurkat-ADCC NF-AT luciferase效应细胞株(以下简称ADCC效应细胞)，通过检测NF-AT信号的激活情况，从而检测抗体的ADCC活性。具体实验过程如下：
1)细胞准备
将靶细胞293T-hCD79b和ADCC效应细胞进行细胞计数。离心去上清，细胞用PBS洗涤两次，用检测培养基(5％low IgG血清的1640培养基(Gibco)重悬，调整ADCC效应细胞浓度为2×10 7个/ml，调整靶细胞浓度为2×10 6个/ml。将两种细胞按照1:1混合，最终效靶比为10:1。
2)铺板：将混合后的细胞铺板，每孔50ul。
3)稀释抗体：梯度稀释抗体样品，第一个孔终浓度为300nM，4倍稀释，共10个梯度，每孔50ul细胞中加入50ul抗体。
4)将上述96孔板于37℃培养箱中孵育7小时。
5)7小时后，取出96孔板，每孔加入解冻的Luciferase assay reagent 100ul。室温孵育20分钟。用酶标仪检测。用GraphPad拟合浓度依赖的曲线。
检测结果如图5所示，人源化的抗体可以有效激活ADCC下游的NF-AT信号通路。
实施例9.本发明双特异性抗体的表达及纯化
按表4组合，将3个不同的抗人CD79b克隆38D9B3.11、11G10.9.p1、34F1.14与2个不同抗人CD3克隆HzSP34.87和HzSP34.24组合分别构建38D9B3.11/sp34.87,38D9B3.11/sp34.24,11G10.9.p1/sp34.87,11G10.9.p1/sp34.24,34F1.14/sp34.87, 34F1.14/sp34.24共计6个双特异性抗体。双特异性抗体分别在HEK293细胞中瞬时表达。表达7天后将获得细胞发酵液过滤澄清，用Protein A柱(Hitrap Mabselect Sure，GE 11-0034-95)进行捕获，得到半抗体。采用A280法检测半抗浓度之后，按摩尔比例1:1混合半抗体。加入适量还原剂GSH，室温反应过夜。超滤去除还原剂，终止反应。之后采用MonoS阳离子交换层析进行精细纯化。将洗脱液超滤并换液到PBS(Gibco，70011-044)中，用质谱进行分子量的测定，并用SEC-HPLC进行纯度鉴定。CD79b.A7v14b/38E4v1是来自专利US20180327492的CD79b/CD3双特异性抗体，采用同样的方法表达。获得的以上7个双特异性抗体用于以下实施例。
表4.CD79b/CD3双特异性抗体列表
  抗CD79b端 抗CD3端
1 38D9B3.11 HzSP34.87
2 38D9B3.11 HzSP34.24
3 11G10.9.p1 HzSP34.87
4 11G10.9.p1 HzSP34.24
5 34F1.14 HzSP34.87
6 34F1.14 HzSP34.24
7 CD79b.A7v14b 38E4v1
具体氨基酸序列表(CDR区由Kabat规则定义)如下：
38D9B3.11重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:1)：GYTFTDYSMH；
HCDR2(SEQ ID NO:2)：WINTETGEPSYADDFKG；
HCDR3(SEQ ID NO:3)：GPY；
重链可变区VH序列(SEQ ID NO:4)：
Figure PCTCN2022108881-appb-000007
重链全长序列(SEQ ID NO:5)：
Figure PCTCN2022108881-appb-000008
轻链CDR序列：
LCDR1(SEQ ID NO:6)：KASQSVDHDVDSYMD；
LCDR2(SEQ ID NO:7)：SASNLES；
LCDR3(SEQ ID NO:8)：QQINEYPYT；
轻链可变区VL序列(SEQ ID NO:9)：
Figure PCTCN2022108881-appb-000009
轻链全长序列(SEQ ID NO:10)：
Figure PCTCN2022108881-appb-000010
11G10.9.p1重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:11)：GYTFTDYWVN；
HCDR2(SEQ ID NO:12)：MIDPSDSETHYNQMFND；
HCDR3(SEQ ID NO:13)：SNYY；
重链可变区VH序列(SEQ ID NO:14)：
Figure PCTCN2022108881-appb-000011
重链全长序列(SEQ ID NO:15)：
Figure PCTCN2022108881-appb-000012
轻链CDR序列如下：
LCDR1(SEQ ID NO:16)：KSSQSLLDSEGKTYLN；
LCDR2(SEQ ID NO:17)：LVSKLDS；
LCDR3(SEQ ID NO:18)：GTHFPLT；
轻链可变区VL序列(SEQ ID NO:19)：
Figure PCTCN2022108881-appb-000013
轻链全长序列(SEQ ID NO:20)：
Figure PCTCN2022108881-appb-000014
34F1.14重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:21)：GYSFTTYWMN；
HCDR2(SEQ ID NO:22)：MIDPSDSETHYNHLFKD；
HCDR3(SEQ ID NO:23)：AIGY；
重链可变区VH序列(SEQ ID NO:24)：
Figure PCTCN2022108881-appb-000015
重链全长序列(SEQ ID NO:25)：
Figure PCTCN2022108881-appb-000016
轻链CDR序列如下：
LCDR1(SEQ ID NO:26)：KSSLSLLDSEGKTYLN；
LCDR2(SEQ ID NO:27)：LVSKLDS；
LCDR3(SEQ ID NO:28)：WQGTHFPLT；
轻链可变区VL序列(SEQ ID NO:29)：
Figure PCTCN2022108881-appb-000017
轻链全长序列(SEQ ID NO:30)：
Figure PCTCN2022108881-appb-000018
HzSP34.87重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:31)：GFTFNTYAMN；
HCDR2(SEQ ID NO:32)：RIRSKYNNYATYYAD；
HCDR3(SEQ ID NO:33)：HYNFGQSYVSWFAY；
重链可变区VH序列(SEQ ID NO:34)：
Figure PCTCN2022108881-appb-000019
重链全长序列(SEQ ID NO:35)：
Figure PCTCN2022108881-appb-000020
轻链CDR序列如下：
LCDR1(SEQ ID NO:36)：RSSTGAVTTSNYAN；
LCDR2(SEQ ID NO:37)：GTNKRAP；
LCDR3(SEQ ID NO:38)：ALWYSNLWV；
轻链可变区VL序列(SEQ ID NO:39)：
Figure PCTCN2022108881-appb-000021
轻链全长序列(SEQ ID NO:40)：
Figure PCTCN2022108881-appb-000022
HzSP34.24重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:41)：GFTFNTYAMN；
HCDR2(SEQ ID NO:42)：RIRSKYNNYATYYADSVKD；
HCDR3(SEQ ID NO:43)：HGNFGQSYVSWFAY；
重链可变区VH序列(SEQ ID NO:44)：
Figure PCTCN2022108881-appb-000023
重链全长序列(SEQ ID NO:45)：
Figure PCTCN2022108881-appb-000024
轻链CDR序列如下：
LCDR1(SEQ ID NO:46)：RSSTGAVTTSNYAN；
LCDR2(SEQ ID NO:47)：GTNKRAP；
LCDR3(SEQ ID NO:48)：ALWYSNLWV；
轻链可变区VL序列(SEQ ID NO:49)：
Figure PCTCN2022108881-appb-000025
轻链全长序列(SEQ ID NO:50)：
Figure PCTCN2022108881-appb-000026
CD79b.A7v14b重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:51)：GYTFTTYYMN；
HCDR2(SEQ ID NO:52)：MIDPSDSETHYNQKFQG；
HCDR3(SEQ ID NO:53)：SLAF；
重链可变区VH序列(SEQ ID NO:54)：
Figure PCTCN2022108881-appb-000027
重链全长序列(SEQ ID NO:55)：
Figure PCTCN2022108881-appb-000028
轻链CDR序列如下：
LCDR1(SEQ ID NO:56)：KSSQSLLDSDGKTYLN；
LCDR2(SEQ ID NO:57)：LVSKLDS；
LCDR3(SEQ ID NO:58)：WQGTHFPQT；
轻链可变区VL序列(SEQ ID NO:59)：
Figure PCTCN2022108881-appb-000029
轻链全长序列(SEQ ID NO:60)：
Figure PCTCN2022108881-appb-000030
38E4v1重链和轻链氨基酸序列
重链CDR序列如下：
HCDR1(SEQ ID NO:61)：GFTFTSYYIH；
HCDR2(SEQ ID NO:62)：WIYPENDNTKYNEKFKD；
HCDR3(SEQ ID NO:63)：DGYSRYYFDY；
重链可变区VH序列(SEQ ID NO:64)：
Figure PCTCN2022108881-appb-000031
重链全长序列(SEQ ID NO:65)：
Figure PCTCN2022108881-appb-000032
轻链CDR序列如下：
LCDR1(SEQ ID NO:66)：KSSQSLLNSRTRKNYLA；
LCDR2(SEQ ID NO:67)：WTSTRKS；
LCDR3(SEQ ID NO:68)：KQSFILRT；
轻链可变区VL序列(SEQ ID NO:69)：
Figure PCTCN2022108881-appb-000033
轻链全长序列(SEQ ID NO:70)：
Figure PCTCN2022108881-appb-000034
polmab重链和轻链氨基酸序列：
重链全长序列(SEQ ID NO:71)：
Figure PCTCN2022108881-appb-000035
轻链全长序列(SEQ ID NO:72)：
Figure PCTCN2022108881-appb-000036
实施例10.本发明抗体亲和力测定
采用表面等离子共振法(Surface plasmon resonance)(Biacore T200)测定本发明抗CD79b/CD3的示例抗体与人CD79b、人CD3以及食蟹猴CD3的结合动力学。(1)抗体与人CD79b-His(Sino biological)的亲和力测定：将50mM N-羟基琥珀酰亚胺(NHS)与200mM 1-乙基-3-(3-二甲基氨丙基)碳二亚胺盐酸盐(EDC)新鲜混匀，以10μL/分钟的流速活化420s。然后将人CD79b-His抗原稀释于10mM Acetate(pH 5.0)中，稀释浓度至1μg/mL后，偶联约50RU。然后以10μL/分钟的流速注入1M乙醇胺420s，对剩余的活化位点进行封闭。实验所用缓冲液为pH 7.4的HBS-EP+溶液，采用high performance模式，将2倍梯度稀释后的抗体(0-80nM)，从低浓度到高浓度以30μl/分钟的流速，每个循环测定一个浓度，依次注入芯片1,2,3,4通道，结合时间180s，解离时间600s。(2)抗体与人CD3E&CD3G-biotin(Sino biological)、猴CD3E&CD3G-biotin(Sino biological)的亲和力测定：将50mM NHS与200mM EDC新鲜混匀，以10μL/分钟的流速活化420s。然后将Streptavidin(Thermo Fisher scientific)蛋白稀释于10mM Acetate(pH 4.5)中，稀释浓度至10μg/mL后，偶联约3000RU。然后以10μL/分钟的流速注入1M乙醇胺420s，对剩余的活化位点进行封闭。将人CD3E&CD3G-biotin、猴CD3E&CD3G-biotin蛋白分别固定在偶联有Streptavidin蛋白的芯片通道上。将2倍梯度稀释后的抗体(0-16nM或0-40nM或0-200nM)，从低浓度到高浓度以30μl/分钟的流速，每个循环测定一个浓度，依次注入芯片1,2,3,4通道，结合时间180s，解离时间300s。
在如以上测定法所述进行的实验中，38D9B3.11/sp34.87,38D9B3.11/sp34.24,11G10.9.p1/sp34.87,11G10.9.p1/sp34.24,34F1.14/sp34.87,34F1.14/sp34.24,CD79b.A7v14b/38E4v1和人CD79b-His的亲和力如表5所示。38D9B3.11/sp34.87,38D9B3.11/sp34.24,11G10.9.p1/sp34.87,11G10.9.p1/sp34.24,34F1.14/sp34.87,34F1.14/sp34.24,CD79b.A7v14b/38E4v1和人CD3E&CD3G(Sino biological)、猴CD3E&CD3G的亲和力如表6、表7所示。
表5.示例抗体与人CD79b的亲和力检测
Figure PCTCN2022108881-appb-000037
表6.示例抗体与人CD3D&E的亲和力检测
Figure PCTCN2022108881-appb-000038
表7.示例抗体与猴CD3D&E的亲和力检测
Figure PCTCN2022108881-appb-000039
实施例11.本发明抗CD79b/CD3抗体与B细胞非霍奇金淋巴瘤细胞系的结合实验
通过流式细胞技术检测CD79b/CD3双特异性抗体与CD79b阳性的B细胞非霍奇金淋巴瘤细胞系的结合能力。
BJAB(美国AddexBio，货号C0003016)、WSU-DLCL2(南京科佰生物，货号CBP60273)按照常规操作培养传代。细胞离心重悬后计数，将细胞密度调整至4X10 6cell/ml倒于加样槽中,用排枪以每孔50ul接种于96孔板中。每孔50ul细胞中加入50ul梯度稀释的抗体样品，然后放入37℃5％CO2的细胞培养箱中孵育30分钟。400g离心5分钟甩板，加入200ul PBS 400g 5分钟离心甩板,重复3次。加入山羊抗人IgG PE(1:200)室温避光孵育30分钟，200ul PBS洗2次甩板；重悬于100ul PBS，流式细胞仪读数。拟合曲线，计算EC50值。
在如以上测定法所述进行的实验中，示例抗体与CD79b高表达细胞系BJAB细胞表面的CD79b结合见图6；示例抗体与CD79b低表达细胞系WSU-DLCL2细胞表面的CD79b结合见图7。
实施例12.本发明抗CD79b/CD3抗体对Jurkat-NFAT-Luc细胞的激活实验
CD79b/CD3双抗同时与B细胞非霍奇金淋巴瘤细胞表面的CD79b和Jurkat-NFAT-Luc细胞表面的CD3 结合，通过CD79b依赖性的CD3交联，激活NFAT-Luc下游信号通路。本研究利用荧光素酶报告基因法检测Jurkat-NFAT-Luc细胞与CD79b阳性的细胞共培养条件下，通过检测加入示例抗体过夜培养后荧光素酶的表达情况反映抗体激活能力的强弱。
实验方法
Assay培养基配制：10％FBS+90％RPMI Medium 1640
Bio-Glo Luciferase Assay System检测液配制：将Bio-Glo TM缓冲液(Promega，G7940)融化，加入Bio-GloTM底物(Promega，G7940)，混匀，于-40℃冰箱保存。
1、取BJAB,WSU-DLCL2,NUGC4和Jurkat-NFAT-Luc细胞，300g离心8min弃上清，使用Assay培养基重悬BJAB细胞和Jurkat-NFAT-Luc细胞，细胞计数，调整细胞密度，其中细胞密度均为6.0×10 5，按照1:1的比例将肿瘤细胞和Jurkat-NFAT-Luc细胞混合备用。
2、取96孔白色细胞培养板，每孔加入100μL细胞悬液以及梯度稀释的待测抗体，过夜孵育。
3、取出Bio-Glo Luciferase Assay System检测液于室温融化。
4、取出步骤2孵育的样品，每孔加入80μL Bio-Glo Luciferase Assay System检测液。
5、酶标仪(Molecular Device，SpectraMax I3)读数。
在如以上测定法所述进行的实验中，示例抗体能够剂量依赖性地激活NFAT信号(见图8A，8B)，示例抗体对非靶细胞NUGC4未显示出激活作用(见图8C)。
实施例13.本发明抗CD79b/CD3抗体对B细胞非霍奇金淋巴瘤细胞系的杀伤实验
CD79b/CD3双抗同时与B细胞非霍奇金淋巴瘤细胞表面的CD79b和原代T细胞表面的CD3结合，通过CD79b依赖性的CD3交联，激活T细胞，介导T细胞对CD79b阳性肿瘤细胞的杀伤。本研究利用Propidium Iodide染色(PI)法检测人CD8+T细胞与CD79b阳性的细胞共培养条件下，加入示例抗体48小时检测肿瘤细胞PI阳性的比率，从而评估人CD8+T细胞对CD79b阳性肿瘤细胞的杀伤能力。
从液氮罐中取出PBMC于37℃快速融化，滴加入预热的含10％FBS的1640培养基(含0.1％DNA酶)中，得混合液10ml。400g离心5分钟，用10ml的含10％FBS的1640培养基重悬，并加入10μl DNA酶，37℃、5％CO2，静置2小时。使用EasySep TM人CD8+T细胞富集试剂盒分离人CD8+T细胞，按照说明书使用。使用含10％FBS的1640培养基调整人CD8+T细胞密度至1×10 6个/ml，作为效应细胞。CD79b阳性细胞BJAB和WSU-DLCL2作为靶细胞，NUGC4作为非靶细胞，400g离心5分钟，用含10％FBS的1640培养基重悬，加入CellTrace Far Red Cell染液(THERMO FISHER，C34564)孵育30分钟，400g离心5分钟，用含10％FBS的1640培养基重悬，并将细胞密度调整为2×10 5cell/ml。按照1:1将肿瘤细胞和人CD8+T细胞悬液混匀，取(公共)96孔圆底培养板(有盖)，每孔加入200μl细胞悬液和梯度稀释的待测抗体。放入二氧化碳培养箱，于37℃刺激48小时。400g，5分钟离心，去除上清，每孔100ul PBS(含1:1000稀释的Propidium Iodide Solution)重悬细胞，4℃静置10min，流式细胞仪(BD,FACS CELESTA) 读数。
在如以上测定法所述进行的实验中，示例抗体能够剂量依赖性地诱导人CD8+T细胞对BJAB和WSU-DLCL2靶细胞的杀伤作用(见图9A，9B)，示例抗体对非靶细胞NUGC4未显示出杀伤作用(见图9C)。
实施例14.本发明抗CD79b/CD3抗体对人B细胞非霍奇金淋巴瘤细胞系的杀伤过程中伴随的T细胞激活和细胞因子释放水平
本研究在B细胞非霍奇金淋巴瘤细胞系和人T细胞共孵育体系中加入梯度稀释的示例抗体，18小时后，通过流式法检测人T细胞CD25和CD69双阳性细胞百分比，从而评估抗体介导的人T细胞和CD79b阳性肿瘤细胞共孵育体系中T细胞的激活程度。利用多因子检测试剂盒(Human Th1/Th2/Th17,BD)同时检测多种细胞因子的水平从而评估抗体介导的人T细胞和CD79b阳性肿瘤细胞共孵育体系中T细胞释放细胞因子的能力。
实验过程
人CD8+T细胞激活以及细胞因子释放检测：
从液氮罐中取出PBMC于37℃快速融化，滴加入预热的含10％FBS的1640培养基(含0.1％DNA酶)中，得混合液10ml。400g离心5分钟，用10ml的含10％FBS的1640培养基重悬，并加入10μl DNA酶，37℃、5％CO2，静置2小时。使用EasySep TM人CD8+T细胞富集试剂盒分离人CD8+T细胞，按照说明书使用。使用含10％FBS的1640培养基调整人CD8+T细胞密度至1×10 6个/ml，作为效应细胞，用含10％FBS的1640培养基重悬，并将肿瘤细胞密度调整为2×10 5cell/ml。按照1:1将肿瘤细胞和人CD8+T细胞悬液混匀，取(公共)96孔圆底培养板(有盖)，每孔加入200μl细胞悬液和梯度稀释的待测抗体(最高浓度100nM，3倍稀释，12个梯度)。放入二氧化碳培养箱，于37℃刺激18小时。400g，5分钟离心，每孔100ul PBS(含1:100稀释的APC anti-human CD8a,FITC anti-human CD69,PE anti-human CD25)重悬细胞，4℃静置30min，洗净，流式细胞仪(BD,FACS CELESTA)读数。同时，收取上清，按照检测试剂盒(Human Th1/Th2/Th17kit，BD)说明书检测细胞因子TNFα，IFN-γ的含量。
人CD4+T细胞激活检测：
从液氮罐中取出PBMC于37℃快速融化，滴加入预热的含10％FBS的1640培养基(含0.1％DNA酶)中，得混合液10ml。400g离心5分钟，用10ml的含10％FBS的1640培养基重悬，并加入10μl DNA酶，37℃、5％CO2，静置2小时。使用EasySep TM人CD4+T细胞富集试剂盒分离人CD4+T细胞，按照说明书使用。使用含10％FBS的1640培养基调整人CD4+T细胞密度至1×10 6个/ml，作为效应细胞，用含10％FBS的1640培养基重悬，并将肿瘤细胞密度调整为2×10 5cell/ml。按照1:1将肿瘤细胞和人CD4+T细胞悬液混匀，取(公共)96孔圆底培养板(有盖)，每孔加入200μl细胞悬液和梯度稀释的待测抗体。放入二氧化碳培养箱，于37℃刺激18小时。400g，5分钟离心，去除上清，每孔100ul PBS(含1:100稀释的APC anti-human CD4,FITC anti-human CD69,PE anti-human CD25)重悬细胞，4℃静置30min，洗净，流式细胞仪(BD,FACS CELESTA)读数。
实验结果
在如以上测定法所述进行的实验中，示例抗体诱导的CD8+T对BJAB细胞的杀伤过程伴随的CD8+激活程度见图10A；示例抗体诱导的CD8+T对Ramos细胞的杀伤过程伴随的CD8+激活程度见图10B；示例抗体诱导的CD8+T对WSU-DLCL2细胞的杀伤过程伴随的CD8+激活程度见图10C；示例抗体诱导的CD8+T对NUGC4细胞的杀伤过程伴随的CD8+激活程度见图10D。示例抗体诱导的CD8+T对各细胞的杀伤过程伴随的IFN-γ释放水平见图11；示例抗体诱导的CD8+T对各细胞的杀伤过程伴随的TNFα释放水平见图12。示例抗体诱导的CD4+T和BJAB细胞共孵育过程伴随的CD4+激活程度见图13A；示例抗体诱导的CD4+T和Ramos细胞共孵育过程伴随的CD4+激活程度见图13B；示例抗体诱导的CD4+T和WSU-DLCL2细胞共孵育过程伴随的CD4+激活程度见图13C；示例抗体诱导的CD4+T和NUGC4细胞共孵育过程伴随的CD4+激活程度见图13D。在有CD79b阳性的肿瘤细胞存在时，示例抗体均可剂量依赖性地激活从PBMC分离的CD8+T和CD4+T细胞，并且T细胞的激活程度与CD3的亲和力存在一定的相关性：抗CD3亲和力越高则对T细胞激活能力越强。
实施例15.示例抗体促进人CD8+T细胞的增殖能力的实验
利用CellTrace Far Red Cell Proliferation Kit标记PBMC分离的CD8+T细胞，然后将标记好的人CD8+T细胞和肿瘤细胞共培养，加入浓度梯度稀释的示例抗体，96小时后利用流式细胞仪检测CD8+T细胞的增殖情况。
实验步骤
人CD8+T细胞分离:从液氮罐中取出PBMC于37℃快速融化，将细胞缓慢加入37℃(含0.1％DNA酶)的10ml的含10％FBS的1640培养基中，300g，8分钟，25℃离心，去上清后，用37℃(含0.1％DNA酶)的10％FBS的1640培养基重悬于T75中于37℃5％CO2培养箱，静置3小时。使用EasySep TM人CD8+T细胞富集试剂盒分离人CD8+T细胞，按照说明书使用。使用含10％FBS的1640培养基调整人CD8+T细胞密度至5×10 5个/ml，作为效应细胞，用含10％FBS的1640培养基重悬，并将肿瘤细胞密度调整为1×10 5cell/ml。按照1:1将肿瘤细胞和人CD8+T细胞悬液混匀，取(公共)96孔圆底培养板(有盖)，每孔加入200μl细胞悬液和梯度稀释的待测抗体。放入二氧化碳培养箱，于37℃刺激72小时。400g，5分钟离心，去除上清，每孔100ul PBS(含1:100稀释的PE anti-human CD8)重悬细胞，4℃静置30min，洗净，流式细胞仪(BD,FACS CELESTA)读数。
实验结果
在如以上测定法所述进行的实验中，示例抗体在CD79b阳性的细胞存在时，可以在体外有效刺激CD8+T细胞增殖(见图14A，914和14C)；而在CD79b阴性的NUGC4细胞存在时，示例抗体无CD79b非依赖性的非特异性的CD8+T细胞的增殖(见图14D)。
实施例16.示例抗体促进人CD4+T细胞的增殖能力的实验
示例抗体在CD79b阳性的肿瘤细胞存在时，在体外可以剂量依赖性地刺激人CD4+T细胞增殖。而 在CD79b阴性的NUGC4细胞存在时，示例抗体无CD79b非依赖性的非特异性的人CD4+T细胞的增殖。
实验步骤
人CD4+T细胞分离:从液氮罐中取出PBMC于37℃快速融化，将细胞缓慢加入37℃(含0.1％DNA酶)的10ml的含10％FBS的1640培养基中，300g，8分钟，25℃离心，去上清后，用37℃(含0.1％DNA酶)的10％FBS的1640培养基重悬于T75中于37℃5％CO2培养箱，静置3小时。使用EasySep TM人CD4+T细胞富集试剂盒分离人CD4+T细胞，按照说明书使用。使用含10％FBS的1640培养基调整人CD4+T细胞密度至5×10 5个/ml，作为效应细胞，用含10％FBS的1640培养基重悬，并将肿瘤细胞密度调整为1×10 5cell/ml。按照1:1将肿瘤细胞和人CD4+T细胞悬液混匀，取(公共)96孔圆底培养板(有盖)，每孔加入200μl细胞悬液和梯度稀释的待测抗体。放入二氧化碳培养箱，于37℃刺激72小时。400g，5分钟离心，去除上清，每孔100ul PBS(含1:100稀释的FITC anti-human CD4)重悬细胞，4℃静置30min，洗净，流式细胞仪(BD,FACS CELESTA)读数。
实验结果
在如以上测定法所述进行的实验中，示例抗体在CD79b阳性的细胞存在时，可以在体外有效刺激CD4+T细胞增殖(见图15A，15B和15C)；而在CD79b阴性的NUGC4细胞存在时，示例抗体无CD79b非依赖性的非特异性的CD4+T细胞的增殖(15D)。
实施例17.本发明抗CD79b/CD3抗体动物体内药效试验
本研究采用人B细胞非霍奇金淋巴瘤细胞系WSU-DLCl2和Ramos细胞接种NOG小鼠的PBMC模型来测定示例抗体的抗肿瘤作用。
示例抗体在WSU-DLCL2荷瘤人源化小鼠模型体内的抗肿瘤药效
实验步骤
雌性NOG小鼠(14-17g)购自北京维通利华实验动物技术有限公司。等级为SPF级。小鼠在到达后驯化检疫7天，随后开始研究。
小鼠静脉注射PBMC细胞，4x10 6个/只，接种体积200ul/只。WSU-DLCL2细胞在PBMC注射后第三天接种。将WSU-DLCL2细胞进行常规传代培养，离心收集细胞，以PBS分散WSU-DLCL2细胞，NOG小鼠右侧背腹部剃毛接种WSU-DLCL2细胞，6x10 6个/只，接种体积200ul/只。
给药：WSU-DLCL2细胞接种后第8天，根据小鼠瘤体积进行分组(每组8只)给药。每3-4天给药一次,总共给药4次。每周2次监测小鼠瘤体积与体重。接种后第22天计算相对肿瘤抑制率(TGI％)，计算公式如下：TGI％＝100％×(hIgG对照组肿瘤体积–治疗组肿瘤体积)/(hIgG对照组肿瘤体积–hIgG对照组初始肿瘤体积)，对照组初始肿瘤体～90mm3。肿瘤体积测定：采用游标卡尺测定肿瘤的最大长轴(L)和最大宽轴(W)，肿瘤体积按如下公式计算：V＝L×W2/2。采用电子天平测定体重。在整个研究期间，当 肿瘤达到端点时或当小鼠具有>20％体重减轻时，使小鼠安乐死。统计肿瘤大小，计算肿瘤抑制率(TGI％)。
实验结果
肿瘤生长曲线见图16，示例抗体可以显著抑制WSU-DLCL2细胞的生长，在第22天统计肿瘤大小，并计算出肿瘤抑制率。与hIgG对比，示例抗体38D9B3.11/sp34.87，38D9B3.11/sp34.24和11G10.9.p1/sp34.24的肿瘤抑制率分别为78％，93％和67％。而CD79b.A7v14b/38E4v1的TGI只有36％。同时在给药的小鼠组中，均没有发现体重明显减轻的现象。
示例抗体在Ramos荷瘤人源化小鼠模型体内的抗肿瘤药效
实验步骤
雌性NOG小鼠(14-17g)购自北京维通利华实验动物技术有限公司。等级为SPF级，小鼠在到达后驯化检疫7天，随后开始研究。
用0.1％DNA酶预热过的RPMI-1640培养基复苏PBMC细胞，然后用PBS分散PBMC细胞，制备成细胞浓度为20×10 6个/mL细胞悬液。小鼠静脉注射PBMC细胞悬液，0.2mL/只，即接种量为4×10 6个细胞/只小鼠。
Ramos细胞进行常规传代培养用于后续体内实验。PBMC细胞接种7天后，用PBS与基质胶(Matrigel)以1:1的比例分散Ramos细胞，制备成细胞浓度为7.5×10 6个/mL细胞悬液。NOG小鼠右侧背部剃毛，皮下注射Ramos细胞悬液，0.2mL/只，即接种量为1.5×10 6个细胞/只小鼠。
肿瘤细胞接种6天后，根据小鼠瘤体积进行分组(每组6只)给药，每3-4天一次，连续给药4次。给药方式为腹腔注射，给药体积为10ml/kg/次。每周2次监测小鼠瘤体积与体重，监测至20天结束。
接种后第20天计算相对肿瘤抑制率(TGI％)，计算公式如下：TGI％＝100％×(hIgG对照组肿瘤体积–治疗组肿瘤体积)/(hIgG对照组肿瘤体积–hIgG对照组给药前肿瘤体积)。肿瘤体积测定：采用游标卡尺测定肿瘤的最大长轴(L)和最大宽轴(W)，肿瘤体积按如下公式计算：V＝L×W2/2。采用电子天平测定体重。
实验结果
肿瘤生长曲线见图17，示例抗体可以显著抑制Ramos的生长，在第20天统计肿瘤大小，并计算出肿瘤抑制率。示例抗体38D9B3.11/sp34.87，38D9B3.11/sp34.24和11G10.9.p1/sp34.24的肿瘤抑制率分别为76％，90％和100％。CD79b.A7v14b/38E4v1的TGI和38D9B3.11/sp34.87类似，77％。同时在给药的小鼠组中，均没有发现体重明显减轻的现象。
实施例18.本发明抗CD79b/CD3抗体动物体内PK试验
本研究利用尾静脉给药的方法，向雌性Balb/C小鼠注射10mg/kg的38D9B3.11/sp34.87，38D9B3.11/sp34.24和11G10.9.p1/sp34.24，从而研究其在小鼠体内的药代动力学性质。小鼠给药后分别在 0.083hr、0.5hr、2hr、6hr、24hr、48hr、4day、7day、14day和21day时间点时经眼球取血，血液于4℃3000rpm离心10min，收集血清。利用ELISA测定血清中抗体含量，计算获得38D9B3.11/sp34.87，38D9B3.11/sp34.24和11G10.9.p1/sp34.24在小鼠体内的半衰期。实验结果如图18，38D9B3.11/sp34.87，38D9B3.11/sp34.24和11G10.9.p1/sp34.24在小鼠体内的半衰期分别为10.4天，7.3天和7.0天，三者均具有与正常的单抗类似的PK。

Claims (27)

  1. 结合CD79b的抗体或其抗原结合片段，其包含重链可变区VH和轻链可变区VL，其中，
    (i)所述VH包含SEQ ID NO:4所示的VH中所含的三个互补决定区域(CDR)HCDR1、HCDR2和HCDR3，并且所述VL包含SEQ ID NO:9所示的VL中所含的LCDR1、LCDR2和LCDR3；
    或
    (ii)所述VH包含SEQ ID NO:14所示的VH中所含的三个互补决定区域(CDR)HCDR1、HCDR2和HCDR3，并且所述VL包含SEQ ID NO:19所示的VL中所含的LCDR1、LCDR2和LCDR3。
  2. 结合CD79b的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中
    (i)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1或SEQ ID NO:11所示的氨基酸序列或由所述氨基酸序列组成；HCDR2包含SEQ ID NO:2或SEQ IDNO:12所示的氨基酸序列或由所述氨基酸序列组成；HCDR3包含SEQ ID NO:3或SEQ ID NO:13所示的氨基酸序列或由所述氨基酸序列组成；
    和/或
    (ii)其中所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ IDNO:6或SEQ ID NO:16所示的氨基酸序列或由所述氨基酸序列组成；LCDR2包含SEQ ID NO:7或SEQID NO:17所示的氨基酸序列或由所述氨基酸序列组成；LCDR3包含SEQ ID NO:8或SEQ ID NO:18所示的氨基酸序列或由所述氨基酸序列组成。
  3. 根据权利要求2所述的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中
    1)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1所示的氨基酸序列或由所述氨基酸序列组成；HCDR2包含SEQ ID NO:2所示的氨基酸序列或由所述氨基酸序列组成；HCDR3包含SEQ ID NO:3所示的氨基酸序列或由所述氨基酸序列组成；所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6所示的氨基酸序列或由所述氨基酸序列组成；LCDR2包含SEQ ID NO:7所示的氨基酸序列或由所述氨基酸序列组成；LCDR3包含SEQ ID NO:8所示的氨基酸序列或由所述氨基酸序列组成；
    或
    2)所述VH包含互补决定区域(CDR)HCDR1、HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11所示的氨基酸序列或由所述氨基酸序列组成；HCDR2包含SEQ ID NO:12所示的氨基酸序列或由所述氨基酸序列组成；HCDR3包含SEQ ID NO:13所示的氨基酸序列或由所述氨基酸序列组成；所述VL包含互补决定区域(CDR)LCDR1、LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16所示的氨基酸序列或由所述氨基酸序列组成；LCDR2包含SEQ ID NO:17所示的氨基酸序列或由所述氨基酸序列组成；LCDR3包含SEQ ID NO:18所示的氨基酸序列或由所述氨基酸序列组成。
  4. 权利要求1至3中任一项的抗体或其抗原结合片段，其包含重链可变区VH和/或轻链可变区VL，其中，
    (a)重链可变区VH
    (i)包含与SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；或者
    (ii)包含SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列或由所述氨基酸序列组成；或者
    (iii)包含与SEQ ID NO:4或SEQ ID NO:14所示的氨基酸序列相比具有1-10个氨基酸置换、插入或缺失的氨基酸序列或由所述氨基酸序列组成；
    和/或
    (b)轻链可变区VL
    (i)包含与SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；
    (ii)包含SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列或由所述氨基酸序列组成；或者
    (iii)包含与SEQ ID NO:9或SEQ ID NO:19所示的氨基酸序列相比具有1-10个氨基酸置换、插入或缺失的氨基酸序列或由所述氨基酸序列组成。
  5. 根据权利要求4所述的抗体或其抗原结合片段，其包含
    (1)包含与SEQ ID NO:4所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的重链可变区VH，和包含与SEQ ID NO:9所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的轻链可变区VL；
    或
    (2)包含与SEQ ID NO:14所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序或由所述氨基酸序列组成列的重链可变区VH，和包含与SEQ ID NO:19所示的氨基酸序列具有至少90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的轻链可变区VL。
  6. 根据权利要求5所述的抗体或其抗原结合片段，其包含
    (1)包含SEQ ID NO:4所示的氨基酸序列或由所述氨基酸序列组成的重链可变区VH和包含SEQ IDNO:9所示的氨基酸序列或由所述氨基酸序列组成的轻链可变区VL；
    或
    (2)包含SEQ ID NO:14所示的氨基酸序列或由所述氨基酸序列组成的重链可变区VH和包含SEQ IDNO:19所示的氨基酸序列或由所述氨基酸序列组成的轻链可变区VL。
  7. 权利要求1至6中任一项的抗体或其抗原结合片段，其包含重链和/或轻链，其中
    (a)重链
    (i)包含与SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；
    (ii)包含SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列或由所述氨基酸序列组成；或者
    (iii)包含与SEQ ID NO:5或SEQ ID NO:15所示的氨基酸序列相比具有1-10个氨基酸置换、插入或缺失的氨基酸序列或由所述氨基酸序列组成；
    和/或
    (b)轻链
    (i)包含与SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；
    (ii)包含SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列或由所述氨基酸序列组成；或者
    (iii)包含与SEQ ID NO:10或SEQ ID NO:20所示的氨基酸序列相比具有1-10个氨基酸置换、插入或缺失的氨基酸序列或由所述氨基酸序列组成。
  8. 根据权利要求7所述的抗体或其抗原结合片段，其包含
    (1)包含与SEQ ID NO:5所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的重链，和包含与SEQ ID NO:10所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的轻链；
    或
    (2)包含与SEQ ID NO:15所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成的重链，和包含与SEQ ID NO:20所示的氨基酸序列具有至少85％、90％、91％、92％、93％、94％、95％、96％、97％、98％或99％同一性的氨 基酸序列或由所述氨基酸序列组成的轻链。
  9. 根据权利要求8所述的抗体或其抗原结合片段，其包含
    (1)包含SEQ ID NO:5所示的氨基酸序列的重链或由所述氨基酸序列组成和包含SEQ ID NO:10所示的氨基酸序列或由所述氨基酸序列组成的轻链；
    或
    (2)包含SEQ ID NO:15所示的氨基酸序列或由所述氨基酸序列组成的重链和包含SEQ ID NO:20所示的氨基酸序列或由所述氨基酸序列组成的轻链。
  10. 根据权利要求1至9中任一项所述的抗体或其抗原结合片段，其中所述抗体是IgG1形式的抗体。
  11. 根据权利要求1至10中任一项所述的抗体或其抗原结合片段，其中所述抗体是单克隆抗体、嵌合抗体、人源化的抗体或人抗体、双特异性或多特异性抗体分子，所述抗原结合片段是以下的抗体片段：Fab、Fab’、Fab’-SH、Fv、单链抗体(例如scFv)或(Fab’) 2、单结构域抗体、双抗体(dAb)、骆驼科抗体(重链抗体)或线性抗体。
  12. 根据权利要求1-11所述的抗体或其抗原结合片段，其特征在于，其为双特异性抗体，包含第一重链，第一轻链，第二重链和第二轻链，其中所述第一重链和第一轻链包含结合CD79b的抗原位点，且优选地，所述第二重链和第二轻链包含结合CD3的抗原结合位点。
  13. 根据权利要求12所述的抗体或其抗原结合片段，其特征在于，
    1)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:7的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQID NO:8的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:2的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:3的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ IDNO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
    2)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:6的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:7的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQID NO:8的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:1的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:2的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:3的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ IDNO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成；
    3)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:17的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:18的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:12的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:13的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQID NO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
    4)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:16的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:17的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:18的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:11的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:12的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:13的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQID NO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成；
    5)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:26的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:27的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQID NO:28的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:21的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:22的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:23的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:31的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:32的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:33的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQID NO:36的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:37的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:38的氨基酸序列或由所述氨基酸序列组成；
    或
    6)第一轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQ ID NO:26的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:27的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:28的氨基酸序列或由所述氨基酸序列组成，第一重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:21的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:22的氨基 酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:23的氨基酸序列或由所述氨基酸序列组成；第二重链包含HCDR1，HCDR2和HCDR3，其中HCDR1包含SEQ ID NO:41的氨基酸序列或由所述氨基酸序列组成，HCDR2包含SEQ ID NO:42的氨基酸序列或由所述氨基酸序列组成，HCDR3包含SEQ ID NO:43的氨基酸序列或由所述氨基酸序列组成，第二轻链包含LCDR1，LCDR2和LCDR3，其中LCDR1包含SEQID NO:46的氨基酸序列或由所述氨基酸序列组成，LCDR2包含SEQ ID NO:47的氨基酸序列或由所述氨基酸序列组成，LCDR3包含SEQ ID NO:48的氨基酸序列或由所述氨基酸序列组成。
  14. 根据权利要求12-13所述的抗体或其抗原结合片段，其特征在于，
    1)第一轻链包含SEQ ID NO:9所示VL，第一重链包含SEQ ID NO:4所示VH，第二重链包含SEQID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；
    2)第一轻链包含SEQ ID NO:9所示VL，第一重链包含SEQ ID NO:4所示VH，第二重链包含SEQID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL；
    3)第一轻链包含SEQ ID NO:19所示VL，第一重链包含SEQ ID NO:14所示VH，第二重链包含SEQID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；
    4)第一轻链包含SEQ ID NO:19所示VL，第一重链包含SEQ ID NO:14所示VH，第二重链包含SEQID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL；
    5)第一轻链包含SEQ ID NO:29所示VL，第一重链包含SEQ ID NO:24所示VH，第二重链包含SEQID NO:34所示VH，第二轻链包含SEQ ID NO:39所示VL；
    或
    6)第一轻链包含SEQ ID NO:29所示VL，第一重链包含SEQ ID NO:24所示VH，第二重链包含SEQID NO:44所示VH，第二轻链包含SEQ ID NO:49所示VL。
  15. 根据权利要求12-14所述的抗体或其抗原结合片段，其特征在于，
    1)第一轻链包含SEQ ID NO:10的序列或者由SEQ ID NO:10的序列组成；第一重链包含SEQ IDNO:5或者由SEQ ID NO:5组成；第二重链包含SEQ ID NO:35或者由SEQ ID NO:35组成；第二轻链包含SEQ ID NO:40或者由SEQ ID NO:40组成；
    2)第一轻链包含SEQ ID NO:10的序列或者由SEQ ID NO:10的序列组成；第一重链包含SEQ IDNO:5或者由SEQ ID NO:5组成；第二重链包含SEQ ID NO:45或者由SEQ ID NO:45组成；第二轻链包含SEQ ID NO:50或者由SEQ ID NO:50组成；
    3)第一轻链包含SEQ ID NO:20的序列或者由SEQ ID NO:20的序列组成；第一重链包含SEQ IDNO:15或者由SEQ ID NO:15组成；第二重链包含SEQ ID NO:35或者由SEQ ID NO:35组成；第二轻链包含SEQ ID NO:40或者由SEQ ID NO:40组成；
    4)第一轻链包含SEQ ID NO:20的序列或者由SEQ ID NO:20的序列组成；第一重链包含SEQ IDNO:15或者由SEQ ID NO:15组成；第二重链包含SEQ ID NO:45或者由SEQ ID NO:45组成；第二轻链包含SEQ ID NO:50或者由SEQ ID NO:50组成；
    5)第一轻链包含SEQ ID NO:30的序列或者由SEQ ID NO:30的序列组成；第一重链包含SEQ IDNO:25或者由SEQ ID NO:25组成；第二重链包含SEQ ID NO:35或者由SEQ ID NO:35组成；第二轻链包 含SEQ ID NO:40或者由SEQ ID NO:40组成；
    或
    6)第一轻链包含SEQ ID NO:30的序列或者由SEQ ID NO:30的序列组成；第一重链包含SEQ IDNO:25或者由SEQ ID NO:25组成；第二重链包含SEQ ID NO:45或者由SEQ ID NO:45组成；第二轻链包含SEQ ID NO:50或者由SEQ ID NO:50组成。
  16. 分离的核酸，其编码根据权利要求1至15中任一项所述的抗体或其抗原结合片段。
  17. 包含根据权利要求16所述的核酸的载体，优选地，所述载体是表达载体。
  18. 包含根据权利要求16所述的核酸或根据权利要求17所述的载体的宿主细胞。
  19. 根据权利要求18所述的宿主细胞，其中所述宿主细胞是原核的或真核的，优选地，其中所述宿主细胞为酵母细胞、哺乳动物细胞或适用于制备抗体或其抗原结合片段的其它细胞；优选地，所述哺乳动物细胞是293细胞或CHO细胞。
  20. 制备抗体或其抗原结合片段的方法，所述方法包括在适于表达编码根据权利要求16所述的核酸的条件下培养根据权利要求18-19任一项所述的宿主细胞，任选地所述方法还包括分离所述抗体或其抗原结合片段，任选地所述方法还包括从所述宿主细胞回收所述抗体或其抗原结合片段。
  21. 免疫缀合物，其包含根据权利要求1至15中任一项所述的抗体或其抗原结合片段以及其它物质。
  22. 药物组合物，其包含根据权利要求1至15中任一项所述的抗体或其抗原结合片段或根据权利要求21所述的免疫缀合物，以及任选地药用辅料，以及任选地还包含一种或多种其它治疗剂。
  23. 根据权利要求1至15中任一项所述的抗体或其抗原结合片段、或根据权利要求21所述的免疫缀合物、或根据权利要求22所述的药物组合物在制备用于预防和/或治疗CD79b和/或CD3相关疾病或病症例如肿瘤的药物中的应用。
  24. 根据权利要求21-22中任一项所述的应用，其中所述抗体或其抗原结合片段、所述免疫缀合物或所述药物组合物能够与一种或多种疗法联合施用。
  25. 根据权利要求23所述的应用，其中所述疗法为治疗方式和/或其它治疗剂；优选地，所述治疗方式包括手术治疗和/或放射疗法。
  26. 预防和/或治疗CD79b和/或CD3相关疾病或病症例的方法，所述方法包括向受试者施用有效量的根据权利要求1-15中任一项所述的抗体或其抗原结合片段、根据权利要求21所述的免疫缀合物或根据权利要求22所述的药物组合物。
  27. 检测样品中抗原CD79b和/或CD3的方法，所述方法包括，
    (a)将样品与根据权利要求1-15任一项所述的抗体或其抗原结合片段接触；以及
    (b)检测抗体或其抗原结合片段与抗原CD79b和/或CD3间的复合物的形成；任选地，抗体是被可检测地标记的。
PCT/CN2022/108881 2021-08-02 2022-07-29 抗CD79b×CD3双特异性抗体及其用途 Ceased WO2023011338A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2022324406A AU2022324406A1 (en) 2021-08-02 2022-07-29 Anti-cd79b×cd3 bispecific antibody and use thereof
CN202280053838.XA CN117897404A (zh) 2021-08-02 2022-07-29 抗CD79b×CD3双特异性抗体及其用途
EP22852051.6A EP4382538A4 (en) 2021-08-02 2022-07-29 BISPECIFIC ANTI-CD79BXCD3 ANTIBODY AND ITS USE
JP2024520682A JP2024536358A (ja) 2021-08-02 2022-07-29 抗ｃｄ７９ｂ×ｃｄ３二重特異性抗体及びその使用
CA3231174A CA3231174A1 (en) 2021-08-02 2022-07-29 Anti-cd79bxcd3 bispecific antibody and use thereof
US18/294,212 US20240343799A1 (en) 2021-08-02 2022-07-29 ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110881474.1 2021-08-02
CN202110881474 2021-08-02

Publications (1)

Publication Number Publication Date
WO2023011338A1 true WO2023011338A1 (zh) 2023-02-09

Family

ID=85154284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/108881 Ceased WO2023011338A1 (zh) 2021-08-02 2022-07-29 抗CD79b×CD3双特异性抗体及其用途

Country Status (7)

Country Link
US (1) US20240343799A1 (zh)
EP (1) EP4382538A4 (zh)
JP (1) JP2024536358A (zh)
CN (1) CN117897404A (zh)
AU (1) AU2022324406A1 (zh)
CA (1) CA3231174A1 (zh)
WO (1) WO2023011338A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118667023B (zh) * 2024-07-16 2025-07-15 上海生物制品研究所有限责任公司 一种抗ox40抗体及其制备方法和应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
CN107108739A (zh) * 2014-12-05 2017-08-29 豪夫迈·罗氏有限公司 抗CD79b抗体和使用方法
CN109311990A (zh) * 2016-06-07 2019-02-05 宏观基因有限公司 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法
CN113015749A (zh) * 2019-09-30 2021-06-22 和铂医药(苏州)有限公司 靶向cd3的抗体、双特异性抗体及其用途
CN113194966A (zh) * 2018-10-03 2021-07-30 柰裴斯生命科学公司 抗cd79抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012468A (es) * 2016-04-15 2019-06-06 Zymeworks Inc Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
KR20230079409A (ko) * 2020-09-29 2023-06-07 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항-cd3 항체 및 이의 용도

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7332581B2 (en) 1999-01-15 2008-02-19 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
CN107108739A (zh) * 2014-12-05 2017-08-29 豪夫迈·罗氏有限公司 抗CD79b抗体和使用方法
US20180327492A1 (en) 2014-12-05 2018-11-15 Genentech, Inc. ANTI-CD79b ANTIBODIES AND METHODS OF USE
CN109311990A (zh) * 2016-06-07 2019-02-05 宏观基因有限公司 使用CD32B x CD79B结合分子治疗炎症性疾病和病症的方法
CN113194966A (zh) * 2018-10-03 2021-07-30 柰裴斯生命科学公司 抗cd79抗体及其应用
CN113015749A (zh) * 2019-09-30 2021-06-22 和铂医药(苏州)有限公司 靶向cd3的抗体、双特异性抗体及其用途

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
AL-LAZIKANI ET AL.: "Standard conformations for the canonical structures of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 273, 1997, pages 927 - 948, XP004461383, DOI: 10.1006/jmbi.1997.1354
ANAND: "Techniques for the Analysis of Complex Genomes", 1992, ACADEMIC PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", July 2008, JOHN WILEY AND SONS
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
CURRENT PROTOCOLS IN IMMUNOLOGY, 1991
DUNCANWINTER, NATURE, vol. 322, 1988, pages 738 - 40
E. MEYERSW MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
ESTEP, P. ET AL.: "High throughput solution Based measurement of antibody-antigen affinity and epitope binning", MABS, vol. 5, no. 2, 2013, pages 270 - 8, XP055105281, DOI: 10.4161/mabs.23049
FLATMAN ET AL., J. CHROMATOGR., 2007, pages 79 - 87
GLOVER: "Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", vol. I&II, 1985, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE
HARLOWLANE: "Antibodies", 1998, COLD SPRING HARBOR LABORATORY PRESS
IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
LIU DELONG, ZHAO JUANJUAN, SONG YONGPING, LUO XIAOFENG, YANG TING: "Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 12, no. 1, 1 December 2019 (2019-12-01), XP093031798, DOI: 10.1186/s13045-019-0703-z *
MANIATIS ET AL.: "Molecular Cloning: A Laboratory Manual", 1982
NEEDLEMAWUNSCH: "J. Mol. Biol.", vol. 48, 1970, pages: 444 - 453
NORTH ET AL.: "A New Clustering of Antibody CDR Loop Conformations", JOURNAL OF MOLECULAR BIOLOGY, vol. 406, 2011, pages 228 - 256, XP028129711, DOI: 10.1016/j.jmb.2010.10.030
PEIYIN WANG; MARIA HRISTOPOULOS; ROBYN CLARK; YVONNE CHEN; DIEGO ELLERMAN; MARY MATHIEU; CHRISTOPH SPIESS; JESSICA LI; CECILE CHAL: "Abstract 3628: T Cell-dependent Bispecific Antibody Anti-CD79b/CD3 as a Potential Therapy for B-cell Malignancies", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 77, no. 13_Suuplement, 1 July 2017 (2017-07-01), US, pages 3628, XP009543147, ISSN: 0008-5472 *
PERBAL: "A Practical Guide to Molecular Cloning", 1984
See also references of EP4382538A4
SHIELD ET AL., JBC, vol. 277, 2002, pages 26733
SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604
SUN L. LAURA; CHEN XIAOCHENG; CHEN YVONNE; DENNIS MARK S.; ELLERMAN DIEGO; JOHNSON CLARISSA; MATHIEU MARY; OLDENDORP AMY; POLSON A: "Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 124, no. 21, 14 November 2014 (2014-11-14), US , pages 4507, XP086741276, ISSN: 0006-4971, DOI: 10.1182/blood.V124.21.4507.4507 *
TILLY HERVé; MORSCHHAUSER FRANCK; BARTLETT NANCY L; MEHTA AMITKUMAR; SALLES GILLES; HAIOUN CORINNE; MUNOZ JAVIER; CHEN ANDY I: "Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 7, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 998 - 1010, XP085725389, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(19)30091-9 *
YANG JUNYI, JIE GUI-TAO: "An antibody-drug conjugate in treating diffuse large B-cell lymphoma: polatuzumab vedotin", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEWDRUGS AND CLINICAL REMEDIES, YAOXUEHUI SHANGHAI FENHUI, SHANGHAI, vol. 39, no. 6, 30 June 2020 (2020-06-30), pages 346 - 348, XP093031800, ISSN: 1007-7669, DOI: 10.14109/j.cnki.xyylc.2020.06.05 *

Also Published As

Publication number Publication date
JP2024536358A (ja) 2024-10-04
AU2022324406A1 (en) 2024-03-14
US20240343799A1 (en) 2024-10-17
CN117897404A (zh) 2024-04-16
EP4382538A4 (en) 2025-10-22
EP4382538A1 (en) 2024-06-12
CA3231174A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP2023075294A (ja) 抗ｃｄ４７抗体及びその応用
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
TWI898054B (zh) 抗ｃｄ３抗體以及其用途
CN112500485B (zh) 一种抗b7-h3抗体及其应用
WO2019141268A1 (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
TW202132351A (zh) 抗cd47/抗pd-l1抗體及其應用
CN113286823B (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
WO2021098822A1 (zh) 一种双特异性抗体
TW202246340A (zh) 抗ctla-4抗體及其應用
WO2023036215A1 (zh) 双特异性抗原结合分子及其应用
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
WO2023011338A1 (zh) 抗CD79b×CD3双特异性抗体及其用途
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
WO2022135468A1 (zh) 抗bcma×cd3双特异性抗体及其用途
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
TW202446793A (zh) 雙特異性抗原結合分子及其應用
WO2024046245A1 (zh) 抗pvrig抗体及其应用
HK40059424B (zh) 抗cd79b抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22852051

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280053838.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2022324406

Country of ref document: AU

Ref document number: AU2022324406

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3231174

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022852051

Country of ref document: EP

Effective date: 20240304

ENP Entry into the national phase

Ref document number: 2022324406

Country of ref document: AU

Date of ref document: 20220729

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024520682

Country of ref document: JP

Kind code of ref document: A